Author: "Ismail Hanta" / Topic: business.industry - Searchworks@Jio Institute Digital Library Search Results

Your search keyword '"Ismail Hanta"' showing total 51 results

Start Over Author "Ismail Hanta" Topic business.industry

51 results on '"Ismail Hanta"'

1. Clinical efficacy, safety, tolerability, and survival outcome of long-term inhaled iloprost treatment in the management of pulmonary arterial hypertension: Data from prospective multicenter observational OPTION study

Author: Bahri Akdeniz, Sümeyye Güllülü, Mehmet Serdar Küçükoğlu, Tamer Sayin, Ismail Hanta, Ersan Atahan, Mehmet Yokuşoğlu, Arzu Baygul, Zeynep Pınar Önen, Gulfer Okumus, Baygül, Arzu (ORCID 0000-0003-0392-6709 & YÖK ID 272290), Küçükoğlu, Mehmet Serdar, Hanta, İsmail, Akdeniz, Bahri, Güllülü, Sümeyye, Atahan, Ersan, Sayın, Tamer, Okumuş, Gülfer, Önen, Zeynep Pınar, Yokuşoğlu, Mehmet, and School of Medicine
Subjects: safety, Targeted Drugs, medicine.medical_specialty, medicine.drug_class, Hypertension, Pulmonary, Lower risk, survival, Insights, Prostacyclin, Pulmonary arterial hypertension, Iloprost, Treatment outcome, Safety, Survival, Oral Sildenafil, pulmonary arterial hypertension, Internal medicine, medicine, Natriuretic peptide, Humans, Cardiac and cardiovascular systems, Diseases of the circulatory (Cardiovascular) system, Prospective Studies, Risk factor, iloprost, Survival rate, Original Investigation, Pulmonary Arterial Hypertension, Combination Therapy, business.industry, Odds ratio, Metaanalysis, Brain natriuretic peptide, Nitric-Oxide, Treatment Outcome, Tolerability, RC666-701, treatment outcome, Female, business, medicine.drug
Abstract: Objective: to evaluate clinical efficacy, safety and tolerability of long-term inhaled iloprost treatment in the daily practice for the management of pulmonary arterial hypertension (PAH). Methods: a total of 115 patients with PAH on inhaled iloprost treatment were included. New York Heart Association (NYHA) functional class, brain natriuretic peptide (BNP) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels, and 6-minute walk distance (6MWD) were recorded at baseline and at 3rd to 24th month visits. Safety and tolerability of iloprost treatment were also evaluated during follow-up, as were the survival, clinical worsening, and the related risk factors. Results: the treatment was associated with an increase in the percentage NYHA functional class II (from 0.0% at enrolment to 36.2% at 24th month visit) patients but no significant difference was noted in 6MWD values. Clinical worsening was observed in 63.5% patients, while survival rate was 69.6%. NT-proBNP levels were significantly higher in non-survivors than in survivors (p=0.042). Cox regression analysis revealed the association of female sex [odds ratio (OR)=0.318; 95% confidence interval (CI), 0.128-0.792; p=0.014] and scleroderma-related PAH (OR=0.347; 95% CI, 0.140-0.860; p=0.022) with significantly lower risk (3.14 fold and 2.88 fold, respectively) of mortality. Conclusion: our findings indicate favorable efficacy, safety, and tolerability of long-term iloprost treatment in the management of PAH, whereas improved NYHA functional class was not accompanied with a significant change in 6MWD values. Patient age was a risk factor for clinical worsening, while female sex, scleroderma subtype, and lower NT-proBNP levels were associated with significantly lower mortality risk., Bayer Türk
Published: 2021

2. Effects of coronavirus disease 2019 (COVID-19) pandemic on the follow-up and treatment of patients with idiopathic pulmonary fibrosis: a cross-sectional multicenter study phone call survey

Author: Ismail Hanta, Can Sevinc, N. Funda Coskun, Güven Özkaya, Ahmet Ursavaş, and Aykut Cilli
Subjects: Idiopathic pulmonary fibrosis, medicine.medical_specialty, Multicenter study, Coronavirus disease 2019 (COVID-19), business.industry, Internal medicine, Pandemic, medicine, medicine.disease, business, Phone call
Published: 2021
Full Text: View/download PDF

3. Overdiagnosis of COPD in Subjects With Unobstructed Spirometry

Author: Lea Sator, Andreas Horner, Michael Studnicka, Bernd Lamprecht, Bernhard Kaiser, Mary Ann McBurnie, A. Sonia Buist, Luisa Gnatiuc, David M. Mannino, Christer Janson, Eric D. Bateman, Peter Burney, NanShan Zhong, Shengming Liu, Jiachun Lu, Pixin Ran, Dali Wang, Jingping Zheng, Yumin Zhou, Ali Kocabaş, Attila Hancioglu, Ismail Hanta, Sedat Kuleci, Ahmet Sinan Turkyilmaz, Sema Umut, Turgay Unalan, Torkil Dawes, Eric Bateman, Anamika Jithoo, Desiree Adams, Edward Barnes, Jasper Freeman, Anton Hayes, Sipho Hlengwa, Christine Johannisen, Mariana Koopman, Innocentia Louw, Ina Ludick, Alta Olckers, Johanna Ryck, Janita Storbeck, Thorarinn Gislason, Bryndis Benedikdtsdottir, Kristin Jörundsdottir, Lovisa Gudmundsdottir, Sigrun Gudmundsdottir, Gunnar Gundmundsson, Ewa Nizankowska-Mogilnicka, Jakub Frey, Rafal Harat, Filip Mejza, Pawel Nastalek, Andrzej Pajak, Wojciech Skucha, Andrzej Szczeklik, Magda Twardowska, Tobias Welte, Isabelle Bodemann, Henning Geldmacher, Alexandra Schweda-Linow, Amund Gulsvik, Tina Endresen, Lene Svendsen, Wan C. Tan, Wen Wang, John Cain, Rebecca Copeland, Dana Hazen, Jennifer Methvin, Renato B. Dantes, Lourdes Amarillo, Lakan U. Berratio, Lenora C. Fernandez, Norberto A. Francisco, Gerard S. Garcia, Teresita S. de Guia, Luisito F. Idolor, Sullian S. Naval, Thessa Reyes, Camilo C. Roa, Ma. Flordeliza Sanchez, Leander P. Simpao, Christine Jenkins, Guy Marks, Tessa Bird, Paola Espinel, Kate Hardaker, Brett Toelle, Peter G.J. Burney, Caron Amor, James Potts, Michael Tumilty, Fiona McLean, E.F.M. Wouters, G.J. Wesseling, Cristina Bárbara, Fátima Rodrigues, Hermínia Dias, João Cardoso, João Almeida, Maria João Matos, Paula Simão, Moutinho Santos, Reis Ferreira, Inga Sif Olafsdottir, Katarina Nisser, Ulrike Spetz-Nyström, Gunilla Hägg, Gun-Marie Lund, Rain Jõgi, Hendrik Laja, Katrin Ulst, Vappu Zobel, Toomas-Julius Lill, Parvaiz A. Koul, Sajjad Malik, Nissar A. Hakim, Umar Hafiz Khan, Rohini Chowgule, Vasant Shetye, Jonelle Raphael, Rosel Almeda, Mahesh Tawde, Rafiq Tadvi, Sunil Katkar, Milind Kadam, Rupesh Dhanawade, Umesh Ghurup, Imed Harrabi, Myriam Denguezli, Zouhair Tabka, Hager Daldoul, Zaki Boukheroufa, Firas Chouikha, Wahbi Belhaj Khalifa, Fernando G. Ayuyao, Cecil Z. Tady, Daniel T. Tan, Sylvia Banal-Yang, Vincent M. Balanag, Maria Teresita N. Reyes, Sanjay Juvekar, Siddhi Hirve, Somnath Sambhudas, Bharat Chaidhary, Meera Tambe, Savita Pingale, Arati Umap, Archana Umap, Nitin Shelar, Sampada Devchakke, Sharda Chaudhary, Suvarna Bondre, Savita Walke, Ashleshsa Gawhane, Anil Sapkal, Rupali Argade, Vijay Gaikwad, Sundeep Salvi, Bill Brashier, Jyoti Londhe, Sapna Madas, Daniel Obaseki, Gregory Erhabor, Olayemi Awopeju, and Olufemi Adewole
Subjects: Pulmonary and Respiratory Medicine, Spirometry, medicine.medical_specialty, Chronic bronchitis, Population, Critical Care and Intensive Care Medicine, 03 medical and health sciences, FEV1/FVC ratio, 0302 clinical medicine, Internal medicine, Wheeze, medicine, 030212 general & internal medicine, Overdiagnosis, education, Asthma, education.field_of_study, COPD, medicine.diagnostic_test, business.industry, medicine.disease, respiratory tract diseases, 030228 respiratory system, medicine.symptom, Cardiology and Cardiovascular Medicine, business
Abstract: Background There are several reports on underdiagnosis of COPD, while little is known about COPD overdiagnosis and overtreatment. We describe the overdiagnosis and the prevalence of spirometrically defined false positive COPD, as well as their relationship with overtreatment across 23 population samples in 20 countries participating in the BOLD Study between 2003 and 2012. Methods A false positive diagnosis of COPD was considered when participants reported a doctor's diagnosis of COPD, but postbronchodilator spirometry was unobstructed (FEV1/FVC > LLN). Additional analyses were performed using the fixed ratio criterion (FEV1/FVC Results Among 16,177 participants, 919 (5.7%) reported a previous medical diagnosis of COPD. Postbronchodilator spirometry was unobstructed in 569 subjects (61.9%): false positive COPD. A similar rate of overdiagnosis was seen when using the fixed ratio criterion (55.3%). In a subgroup analysis excluding participants who reported a diagnosis of "chronic bronchitis" or "emphysema" (n = 220), 37.7% had no airflow limitation. The site-specific prevalence of false positive COPD varied greatly, from 1.9% in low- to middle-income countries to 4.9% in high-income countries. In multivariate analysis, overdiagnosis was more common among women, and was associated with higher education; former and current smoking; the presence of wheeze, cough, and phlegm; and concomitant medical diagnosis of asthma or heart disease. Among the subjects with false positive COPD, 45.7% reported current use of respiratory medication. Excluding patients with reported asthma, 34.4% of those with normal spirometry still used a respiratory medication. Conclusions False positive COPD is frequent. This might expose nonobstructed subjects to possible adverse effects of respiratory medication.
Published: 2019
Full Text: View/download PDF

4. Effects of the COVID-19 pandemic on the follow-up and treatment of patients with idiopathic pulmonary fibrosis: a cross-sectional, multicentre phone call survey

Author: Güven Özkaya, Can Sevinc, Ahmet Ursavaş, Ismail Hanta, Aykut Cilli, and Funda Coşkun
Subjects: Male, adult thoracic medicine, medicine.medical_specialty, Cross-sectional study, Pyridones, thoracic medicine, Psychological intervention, chemistry.chemical_compound, Idiopathic pulmonary fibrosis, COVID-19 Testing, Internal medicine, Pandemic, medicine, Humans, respiratory medicine (see thoracic medicine), Pandemics, Respiratory Medicine, Depression (differential diagnoses), Aged, interstitial lung disease, business.industry, SARS-CoV-2, Interstitial lung disease, COVID-19, General Medicine, Middle Aged, medicine.disease, Idiopathic Pulmonary Fibrosis, Cross-Sectional Studies, Treatment Outcome, chemistry, Anxiety, Medicine, Nintedanib, medicine.symptom, business, Follow-Up Studies
Abstract: ObjectiveTo learn about the attitudes and behaviours of patients with idiopathic pulmonary fibrosis (IPF) in relation to the difficulties experienced during the COVID-19 pandemic.DesignA cross-sectional, multicentre phone call survey.SettingFour university hospitals in Turkey.ParticipantsThe study included patients with IPF receiving antifibrotics for at least 3 months and with doctor appointment and/or scheduled routine blood analysis between March and May 2020 (the first 3 months after the official announcement of the COVID-19 pandemic in Turkey).InterventionsPhone calls (a 5 min interview) were performed in June 2020. A questionnaire and the Hospital Anxiety-Depression Scale were applied.Main outcome measuresPatients’ preferences for disease monitoring, patients’ attitudes and behaviours towards IPF, drug continuation, COVID-19 diagnosis and anxiety/depression status.ResultsThe study included 115 patients with IPF (82 male; mean age, 68.43±7.44 years). Of the patients, 73.9% had doctor appointment and 52.2% had scheduled routine blood testing; 54.5% of patients with doctor appointment self-cancelled their appointments and 53.3% of patients with scheduled routine blood testing did not undergo testing. Of the patients, 32.2% were on nintedanib and 67.8% were on pirfenidone; self-initiated drug discontinuation rate was 22.6%. The percentage of patients communicating with their physicians was 35.7%. The route of communication was by phone (34.8%). The frequency of depression and anxiety was 27.0% and 38.3%, respectively. The rates of drug discontinuation (35.1% vs 16.7%, pConclusionsDuring the COVID-19 pandemic, a significant proportion (>50%) of patients self-cancelled their appointments and nearly a quarter of patients discontinued their medications. Providing a documentation of the problems experienced by patients with IPF about management of the necessary requirements during the COVID-19 pandemic, this study may be a model for patients with chronic diseases.
Published: 2021

5. Morbidity and mortality of surgical lung biopsy in the diagnosis of usual interstitial pneumonia

Author: Ayse Odemis, Levent Dertsiz, Ismail Hanta, Can Sevinc, Celalettin Ibrahim Kocaturk, Aykut Cilli, Kemal Can Tertemiz, Neslihan Fener, Cem Emrah Kalafat, İstinye Üniversitesi, Tıp Fakültesi, Cerrahi Tıp Bilimleri Bölümü, and Kocaturk, Celalettin Ibrahim
Subjects: medicine.medical_specialty, medicine.medical_treatment, Biopsy, Usual Interstitial Pneumonia, Lung biopsy, Video-Assisted Thoracoscopic Surgery, 03 medical and health sciences, Idiopathic pulmonary fibrosis, 0302 clinical medicine, Usual interstitial pneumonia, medicine, Humans, Medical history, Lung, Aged, Retrospective Studies, medicine.diagnostic_test, business.industry, Mortality rate, General Medicine, Middle Aged, respiratory system, medicine.disease, Idiopathic Pulmonary Fibrosis, Surgery, 030220 oncology & carcinogenesis, Cohort, Video-assisted thoracoscopic surgery, 030211 gastroenterology & hepatology, Morbidity, business, Lung Diseases, Interstitial, Surgical Lung
Abstract: Background: Histology represents the major source of information to define a usual interstitial pneumonia (UIP) pattern. However, the procedure is associated with significant morbidity and mortality. The aim of this study was to evaluate morbidity and mortality of surgical lung biopsy (SLB) in diagnosing UIP. Methods: Patients undergoing SLB with the ultimate diagnosis of UIP were studied. Clinical data concerning medical history, histology, pulmonary functions, radiology, length of hospital stay (LOS), morbidity and mortality status were retrospectively recruited from four hospitals. Results: The study included consecutive 93 patients with a SLB diagnosis of UIP. Mean age was 61 ± 8 years, with one third of the patients were ≥65 years. In 58 cases (62.4%), the biopsy was performed by video-assisted thoracoscopic surgery, in 35 (37.7%) by limited thoracotomy. Eighty patients (86%) had possible UIP, 12 (12.9%) had inconsistent with UIP and one (1.1%) had UIP pattern on high-resolution computed tomography. The mean LOS was 5.47 ± 3.16 days. LOS was associated with smoking status (P = 0.024), type of biopsy (P = 0.00), 6-min walk test (P = 0.00) and number of biopsy (P = 0.00). There was no in-hospital and 30-day mortality in our cohort, and 90-day mortality rate was 1.1%. In seven patients (7.5%), we observed postoperative morbidities, predominantly prolonged air leakage (7.5% of all cases). Postoperative morbidity was only associated with the type of SLB. Patients with limited thoracotomy showed greater morbidity rates (17.1% versus 1.7%, P = 0.011). Conclusion: SLB is a relatively safe procedure in the diagnosis of UIP and can be performed in suitable patients with suspected UIP/idiopathic pulmonary fibrosis. WOS:000623102700001 33645001 Q3
Published: 2021

6. Evaluation of efficacy and safety of pirfenidone 200 mg tablets in patients with idiopathic pulmonary fibrosis in a real-life setting

Author: Ahmet Ursavaş, Ismail Hanta, Aykut Cilli, Necmiye Funda Coşkun, Can Sevinc, and Ayse Odemis
Subjects: Adult, Male, Vital capacity, medicine.medical_specialty, Pyridones, Pulmonary function testing, FEV1/FVC ratio, Idiopathic pulmonary fibrosis, DLCO, Internal medicine, Medicine, Humans, Adverse effect, Aged, Retrospective Studies, Aged, 80 and over, business.industry, Anti-Inflammatory Agents, Non-Steroidal, General Medicine, Pirfenidone, Middle Aged, medicine.disease, Idiopathic Pulmonary Fibrosis, Treatment Outcome, Cough, Female, business, Progressive disease, medicine.drug, Tablets
Abstract: Background/aim Phase III trials have demonstrated a significant efficacy and an acceptable safety for pirfenidone in patients having mild to moderate idiopathic pulmonary fibrosis (IPF). Real-life data on the use of pirfenidone 200 mg tablets are limited. This study aimed to investigate the efficacy and safety of pirfenidone 200 mg tablets for the treatment of IPF in a real-life setting. Materials and methods A retrospective, multicenter study conducted in four university hospitals in XXX between January 2017 and January 2019. Clinical records of patients diagnosed with mild to moderate IPF and receiving pirfenidone (200 mg tablets, total 2400 mg/day) were reviewed retrospectively and consecutively. Pulmonary function measurements including forced vital capacity (FVC%) and diffusing capacity of the lungs for carbon monoxide (DLCO%) were analyzed at baseline and after 6-month of pirfenidone treatment. Descriptive statistics were expressed as mean, standard error or median (minimum-maximum), number and percentage, where appropriate. Results The study included 82 patients, of whom 87.8% were males (mean age, 66 years). After 6-month of treatment, 7 patients discontinued the treatment. Of the remaining 75 patients, 71 (94.6%) remained stable, 4 (5.4%) had progressive disease as evident by a decline in the FVC% of at least 10% while on treatment, and 45 (61.3%) had improved cough. At least one adverse event (AE) associated with the treatment was observed in 28 (37.3%) patients. Conclusion Pirfenidone 200 mg was effective and well tolerated and associated with relatively mild and manageable AEs in IPF patients.
Published: 2021

7. Prevalence and population-attributable risk for chronic airflow obstruction in a large multinational study

Author: Peter Burney, Jaymini Patel, Cosetta Minelli, Louisa Gnatiuc, André F. S. Amaral, Ali Kocabaş, Hamid Hacene Cherkaski, Amund Gulsvik, Rune Nielsen, Eric Bateman, Anamika Jithoo, Kevin Mortimer, Talant M. Sooronbaev, Hervé Lawin, Chakib Nejjari, Mohammed Elbiaze, Karima El Rhazi, Jin-Ping Zheng, Pixin Ran, Tobias Welte, Daniel Obaseki, Gregory Erhabor, Asma Elsony, Nada Bakri Osman, Rana Ahmed, Ewa Nizankowska-Mogilnicka, Filip Mejza, David M. Mannino, Cristina Bárbara, Emiel F. M. Wouters, Luisito F. Idolor, Li-Cher Loh, Abdul Rashid, Sanjay Juvekar, Thorarinn Gislason, Mohamed Al Ghobain, Michael Studnicka, Imed Harrabi, Meriam Denguezli, Parvaiz A. Koul, Christine Jenkins, Guy Marks, Rain Jõgi, Hasan Hafizi, Christer Janson, Wan C. Tan, Althea Aquart-Stewart, Bertrand Mbatchou, Asaad Ahmed Nafees, Kirthi Gunasekera, Terry Seemungal, Mahesh Padukudru Anand, Paul Enright, William M. Vollmer, Marta Blangiardo, Fadlalla G. Elfadaly, A. Sonia Buist, Anila Aliko, Donika Bardhi, Holta Tafa, Natasha Thanasi, Arian Mezini, Alma Teferici, Dafina Todri, Jolanda Nikolla, Rezarta Kazasi, Amira Bengrait, Tabarek Haddad, Ibtissem Zgaoula, Maamar Ghit, Abdelhamid Roubhia, Soumaya Boudra, Feryal Atoui, Randa Yakoubi, Rachid Benali, Abdelghani Bencheikh, Nadia Ait-Khaled, Tessa Bird, Paola Espinel, Kate Hardaker, Brett Toelle, Torkil Dawes, Bernd Lamprecht, Lea Schirhofer, Akramul Islam, Syed Masud Ahmed, Shayla Islam, Qazi Shafayetul Islam, Tridib Roy Chowdhury, Sukantha Kumar Chatterjee, Dulal Mia, Shyamal Chandra Das, Mizanur Rahman, Nazrul Islam, Shahaz Uddin, Nurul Islam, Luiza Khatun, Monira Parvin, Abdul Awal Khan, Maidul Islam, Herve Lawin, Arsene Kpangon, Karl Kpossou, Gildas Agodokpessi, Paul Ayelo, Benjamin Fayomi, Atongno Humphrey Ashu, Wen Wang, NanShan Zhong, Shengming Liu, Jiachun Lu, Dali Wang, Jin-ping Zheng, Yumin Zhou, Hendrik Laja, Katrin Ulst, Vappu Zobel, Toomas-Julius Lill, Ayola Akim Adegnika, Isabelle Bodemann, Henning Geldmacher, Alexandra Schweda-Linow, Bryndis Benedikdtsdottir, Kristin Jörundsdottir, Lovisa Gudmundsdottir, Sigrun Gudmundsdottir, Gunnar Gudmundsson, Mahesh Rao, Sajjad Malik, Nissar A. Hakim, Umar Hafiz Khan, Rohini Chowgule, Vasant Shetye, Jonelle Raphael, Rosel Almeda, Mahesh Tawde, Rafiq Tadvi, Sunil Katkar, Milind Kadam, Rupesh Dhanawade, Umesh Ghurup, Siddhi Hirve, Somnath Sambhudas, Bharat Chaidhary, Meera Tambe, Savita Pingale, Arati Umap, Archana Umap, Nitin Shelar, Sampada Devchakke, Sharda Chaudhary, Suvarna Bondre, Savita Walke, Ashleshsa Gawhane, Anil Sapkal, Rupali Argade, Vijay Gaikwad, Sundeep Salvi, Bill Brashier, Jyoti Londhe, Sapna Madas, Akosua Francia Aikman, Bermet M. Estebesova, Meerim Akmatalieva, Saadat Usenbaeva, Jypara Kydyrova, Eliza Bostonova, Ulan Sheraliev, Nuridin Marajapov, Nurgul Toktogulova, Berik Emilov, Toktogul Azilova, Gulnara Beishekeeva, Nasyikat Dononbaeva, Aijamal Tabyshova, Wezzie Nyapigoti, Ernest Mwangoka, Mayamiko Kambwili, Martha Chipeta, Gloria Banda, Suzgo Mkandawire, Justice Banda, Siti Sholehah, Mohamed C. Benjelloun, Mohamed Elbiaze, E. F. M. Wouters, G. J. Wesseling, Olayemi Awopeju, Olufemi Adewole, Tina Endresen, Lene Svendsen, Asaad A. Nafees, Teresita S. de Guia, Norberto A. Francisco, Camilo C. Roa, Fernando G. Ayuyao, Cecil Z. Tady, Daniel T. Tan, Sylvia Banal-Yang, Vincent M. Balanag, Maria Teresita N. Reyes, Renato. B. Dantes, Renato B. Dantes, Lourdes Amarillo, Lakan U. Berratio, Lenora C. Fernandez, Gerard S. Garcia, Sullian S. Naval, Thessa Reyes, Ma. Flordeliza Sanchez, Leander P. Simpao, Jakub Frey, Rafal Harat, Pawel Nastalek, Andrzej Pajak, Wojciech Skucha, Andrzej Szczeklik, Magda Twardowska, Fátima Rodrigues, Hermínia Dias, João Cardoso, João Almeida, Maria João Matos, Paula Simão, Moutinho Santos, Reis Ferreira, M. Al Ghobain, H. Alorainy, E. El-Hamad, M. Al Hajjaj, A. Hashi, R. Dela, R. Fanuncio, E. Doloriel, I. Marciano, L. Safia, Desiree Adams, Edward Barnes, Jasper Freeman, Anton Hayes, Sipho Hlengwa, Christine Johannisen, Mariana Koopman, Innocentia Louw, Ina Ludick, Alta Olckers, Johanna Ryck, Janita Storbeck, Rajitha Wickremasinghe, Hana A. Elsadig, Nada Bakery Osman, Bandar Salah Noory, Monjda Awad Mohamed, Hasab Alrasoul Akasha Ahmed Osman, Namarig Moham ed Elhassan, Abdel Mu‘is El Zain, Marwa Mohamed Mohamaden, Suhaiba Khalifa, Mahmoud Elhadi, Mohand Hassan, Dalia Abdelmonam, Inga Sif Olafsdottir, Katarina Nisser, Ulrike Spetz-Nyström, Gunilla Hägg, Gun-Marie Lund, Terence Seemungal, Fallon Lutchmansingh, Liane Conyette, Myriam Denguezli, Zouhair Tabka, Hager Daldoul, Zaki Boukheroufa, Firas Chouikha, Wahbi Belhaj Khalifa, Attila Hancioglu, Ismail Hanta, Sedat Kuleci, Ahmet Sinan Turkyilmaz, Sema Umut, Turgay Unalan, Peter G. J. Burney, Hadia Azar, Caron Amor, James Potts, Michael Tumilty, Fiona McLean, Risha Dudhaiya, Mary Ann McBurnie, Suzanne Gillespie, Sean Sullivan, Todd A. Lee, Kevin B. Weiss, Robert L. Jensen, Robert Crapo, John Cain, Rebecca Copeland, Dana Hazen, Jennifer Methvin, RS: NUTRIM - R3 - Respiratory & Age-related Health, Pulmonologie, MUMC+: MA Longziekten (3), and Wellcome Trust
Subjects: Pulmonary and Respiratory Medicine, wa_754, Vital capacity, Passive smoking, multinational study, Respiratory System, AMERICAN THORACIC SOCIETY, Critical Care and Intensive Care Medicine, medicine.disease_cause, LOWER LIMIT, population-attributable risk, Environmental health, medicine, Burden of Obstructive Lung Disease (BOLD) study, PULMONARY-DISEASE, COPD, Population attributable risk, Risk factor, 11 Medical and Health Sciences, History of tuberculosis, business.industry, MORTALITY, ASSOCIATION, GLOBAL BURDEN, medicine.disease, Obstructive lung disease, REFERENCE VALUES, wf_20, chronic airflow obstruction, NEVER-SMOKERS, Relative risk, Attributable risk, OCCUPATION, wf_200, business, wf_600, wb_200
Abstract: Rationale: The Global Burden of Disease program identified smoking and ambient and household air pollution as the main drivers of death and disability from chronic obstructive pulmonary disease (COPD). Objective: To estimate the attributable risk of chronic airflow obstruction (CAO), a quantifiable characteristic of COPD, due to several risk factors. Methods: The Burden of Obstructive Lung Disease study is a cross-sectional study of adults, aged ≥40, in a globally distributed sample of 41 urban and rural sites. Based on data from 28,459 participants, we estimated the prevalence of CAO, defined as a postbronchodilator FEV1-to-FVC ratio less than the lower limit of normal, and the relative risks associated with different risk factors. Local relative risks were estimated using a Bayesian hierarchical model borrowing information from across sites. From these relative risks and the prevalence of risk factors, we estimated local population attributable risks. Measurements and Main Results: The mean prevalence of CAO was 11.2% in men and 8.6% in women. The mean population attributable risk for smoking was 5.1% in men and 2.2% in women. The next most influential risk factors were poor education levels, working in a dusty job for ≥10 years, low body mass index, and a history of tuberculosis. The risk of CAO attributable to the different risk factors varied across sites. Conclusions: Although smoking remains the most important risk factor for CAO, in some areas, poor education, low body mass index, and passive smoking are of greater importance. Dusty occupations and tuberculosis are important risk factors at some sites.
Published: 2021

8. Riociguat treatment in patients with chronic thromboembolic pulmonary hypertension. final safety data from the EXPERT registry

Author: Hossein-Ardeschir Ghofrani, Miguel-Angel Gomez Sanchez, Marc Humbert, David Pittrow, Gérald Simonneau, Henning Gall, Ekkehard Grünig, Hans Klose, Michael Halank, David Langleben, Repke J. Snijder, Pilar Escribano Subias, Lisa M. Mielniczuk, Tobias J. Lange, Jean-Luc Vachiéry, Hubert Wirtz, Douglas S. Helmersen, Iraklis Tsangaris, Joan A. Barberá, Joanna Pepke-Zaba, Anco Boonstra, Stephan Rosenkranz, Silvia Ulrich, Regina Steringer-Mascherbauer, Marion Delcroix, Pavel Jansa, Iveta Šimková, George Giannakoulas, Jens Klotsche, Evgenia Williams, Christian Meier, Marius M. Hoeper, Jorge Caneva, Graciela Tuhay, Mirta Diez, Maria Lujan Talavera, Adriana Acosta, Norberto Vulcano, Martin Bosio, Lorena Maldonado, Sabino Deleo, Luciano Melatini, Anne Keogh, Eugene Kotlyar, John Feenstra, Nathan Dwyer, Heath Adams, Wendy Stevens, Peter Steele, Susanna Proudman, Robert Minson, Glenn Reeves, Melanie Lavender, Benjamin Ng, Michele Mackenzie, Lisa Barry, Margarethe Gruenberger, Charlotte Huber, Irene Lang, Ioana Tilea, Roela Sadushi-Kolici, Judith Löffler-Ragg, Lisa-Theresa Feistmantl, Patrick Evrard, Renaud Louis, Julien Guiot, Marco Naldi, Michel De Pauw, Sanjay Mehta, Rafael Conde Camacho, Patricia Parada Tovar, Alejandro Londoño, Felipe Campo, Paula Garcia, Camila Lema, Mauricio Orozco-Levi, William Martinez, Juan Esteban Gomez, Jens Erik Nielsen-Kudsk, Soren Mellemkjaer, Ly Anton, Alan Altraja, Tapani Vihinen, Tuija Vasankari, Olivier Sitbon, Vincent Cottin, Laurent Têtu, Elise Noël-Savina, Nicole Shearman, Susanne Tayler, Ilona Olzik, Christine Kulka, Jan Grimminger, Marcel Simon, Anna Nolde, Tim Oqueka, Lars Harbaum, Benjamin Egenlauf, Ralf Ewert, Christian Schulz, Sabine Regotta, Tilmann Kramer, Susanne Knoop-Busch, Felix Gerhardt, Stavros Konstantinides, Georgia Pitsiou, Ioannis Stanopoulos, Evdokia Sourla, Sofia Mouratoglou, Haralambos Karvounis, Athanasios Pappas, Dimitrios Georgopoulos, Michail Fanaridis, Ioanna Mitrouska, Lampros Michalis, Konstantinos Pappas, Anna Kotsia, Sean Gaine, Carmine Dario Vizza, Giovanna Manzi, Roberto Poscia, Roberto Badagliacca, Piergiuseppe Agostoni, Noemi Bruno, Stefania Farina, Michele D'Alto, Paola Argiento, Anna Correra, Giovanni Maria Di Marco, Chiara Cresci, Vieri Vannucchi, Elena Torricelli, Alessio Garcea, Alberto Pesci, Luca Sardella, Giuseppe Paciocco, Federico Pane, Andrea Maria D'Armini, Maurizio Pin, Valentina Grazioli, Giulia Massola, Antonio Sciortino, Renato Prediletto, Carolina Bauleo, Edoardo Airò, Rudina Ndreu, Ivana Pavlickova, Claudio Lunardi, Massimiliano Mulè, Silvia Farruggio, Serena Costa, Giuseppe Galgano, Mario Petruzzi, Anna De Luca, Francesco Lombardi, Loris Roncon, Luca Conte, Claudio Picariello, Gil Wirtz, Myriam Alexandre, A. Vonk-Noordegraaf, H. Boogaard, J. Mager, H. Reesink, Leon M. van den Toorn, Karin Boomars, Arne K. Andreassen, Graça Castro, Gonçalves Tania, Rui Baptista, António Marinho, Teresa Shiang, Ana Oliveira, Daniel Coutinho, Joana Sousa, Maria José Loureiro, Débora Repolho, Susana Maria Martins Jesus, Marta Capinha, João Agostinho, Tania Cardoso, Andreia Rocha, Mafalda Espinha, Kyundyul Ivanovich Ivanov, Dalyana Eduardovna Alexeeva, Marina Vadimovna Batalina, Daria Viktorovna Hegya, Tatyana Nikolaevna Zvereva, Sergey Nikolaevich Avdeev, Natalia Anatolievna Tsareva, Albert Sarvatovich Galyavich, Bykov Aleksander Nikolaevich, Evgeny Vladimirovich Filippov, Olga Eduardovna Yakovleva, Olga Borisovna Pavlova, Elena Sergeevna Skripkina, Tamila Vitalievna Martynyuk, Irina Fedorovna Bukatova, Anna Viktorovna Tregubova, Dmitry Yurievich Platonov, Tatyana Mikhaylovna Kolomeytseva, Abdullah Al Dalaan, Abeer Abeer Abdelsayed, Ihab Weheba, Sarferaz Saleemi, Hussam Sakkijha, Marcela Bohacekova, Tatiana Valkovicova, Iveta Farkasova, Carlos Andres Quezada, Lucilla Piccari, Isabel Blanco, Laura Sebastian, Antonio Roman, Manuel Lopez, Remedios Otero, Teresa Elias, Luis Jara, Isabel Asencio, Josefa Jiménez Arjona, Raúl Menor Almagro, Salvador López Cárdenas, Salvador Alcaraz García, Patricia Villanueva Rodríguez, Raquel Lopez, Alberto Garcia, Francisco Fernandez Avilés, Sebastian De La Pava, Raquel Yotti, Gregorio Pérez Peñate, Fernando León Marrero, José Manuel Cifrián Martínez, Amaya Martinez-Meñaca, Lecue Pilar Alonso, Sonia Fernandez Rozas, David Iturbe Fernandez, Victor Mora Cuesta, Stefan Söderberg, Sven-Erik Bartfay, Bengt Rundqvist, Monthir Alfetlawi, Peter Wodlin, Esther Irene Schwarz, Rudolf Speich, Frédéric Lador, Thierry Rochat, Paola Gasche-Soccal, Chih-Hsin Hsu, Tsung-Hsien Lin, Ho-Ming Su, Wen-Ter Lai, Chun Yuan Chu, Po-Chao Hsu, Wen-Chol Voon, Hsueh-Wei Yen, Jacob Yih-Jer Wu, Shu-Hao Wu, Wen-Pin Huang, Man-Cai Fong, Chien-Lung Huang, Ping-Hung Kuo, Yen-Hung Lin, Jiunn-Lee Lin, Chi-Sheng Hung, Cho-Kai Wu, Shih-Hsien Sung, Wei-Chun Huang, Chin-Chang Cheng, Shu-Hung Kuo, Wen-Hwa Wang, Wan-Jing Ho, Tsu-Shiu Hsu, Bülent Mutlu, Halil Atas, Gul Ongen, Zeynep Un, Gulfer Okumus, Ismail Hanta, Paul Corris, Andrew Peacock, Colin Church, Mark Toshner, Michael Newnham, Gastroenterology & Hepatology, Pulmonary Medicine, Pulmonary medicine, ACS - Pulmonary hypertension & thrombosis, and VU University medical center
Subjects: real-world, pulmonary embolism, pyrimidines, MedDRA, data analysis, Peripheral edema, Chronic thromboembolic pulmonary hypertension, randomized controlled trials as topic, Clinical practice, registry, time factors, law.invention, chronic thromboembolic pulmonary hypertension, 0302 clinical medicine, Randomized controlled trial, law, middle aged, Medicine, 030212 general & internal medicine, humans, Hipertensió pulmonar, pyrazoles, clinical practice, aged, female, riociguat, safety, chronic disease, hypertension, pulmonary, male, multicenter studies as topic, prospective studies, recurrence, treatment outcome, registries, medicine.symptom, Safety, medicine.drug, Pulmonary and Respiratory Medicine, medicine.medical_specialty, Registry, hypertension, pulmonary, Hypertension, Pulmonary, Riociguat, Pulmonary hypertension, 03 medical and health sciences, Internal medicine, Adverse effect, business.industry, medicine.disease, Pneumonia, 030228 respiratory system, Real-world, Pulmonary hemorrhage, business
Abstract: Objective: The soluble guanylate cyclase stimulator riociguat is approved for the treatment of adult patients with pulmonary arterial hypertension (PAH) and inoperable or persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) following Phase 3 randomized trials. The EXPosurE Registry RiociguaT in patients with pulmonary hypertension (EXPERT) study was designed to monitor the long-term safety of riociguat in clinical practice. Methods: EXPERT was an international, multicenter, prospective, uncontrolled, non-interventional cohort study of patients treated with riociguat. Patients were followed for at least 1 year and up to 4 years from enrollment or until 30 days after stopping riociguat treatment. Primary safety outcomes were adverse events (AEs) and serious adverse events (SAEs) coded using Medical Dictionary for Regulatory Activities preferred terms and System Organ Classes version 21.0, collected during routine clinic visits and collated via case report forms. Results: In total, 956 patients with CTEPH were included in the analysis. The most common AEs in these patients were peripheral edema/edema (11.7%), dizziness (7.5%), right ventricular (RV)/cardiac failure (7.7%), and pneumonia (5.0%). The most common SAEs were RV/cardiac failure (7.4%), pneumonia (4.1%), dyspnea (3.6%), and syncope (2.5%). Exposure-adjusted rates of hemoptysis/pulmonary hemorrhage and hypotension were low and comparable to those in the long-term extension study of riociguat (Chronic Thromboembolic Pulmonary Hypertension Soluble Guanylate Cyclase–Stimulator Trial [CHEST-2]). Conclusion: Data from EXPERT show that in patients with CTEPH, the safety of riociguat in routine practice was consistent with the known safety profile of the drug, and no new safety concerns were identified. © 2020 The Authors Eli Lilly and Company; Pfizer; Bayer; GlaxoSmithKline; Merck; Actelion Pharmaceuticals; Meso Scale Diagnostics; United Therapeutics Corporation; Novartis Pharma; Merck Sharp and Dohme; GlaxoSmithKline Australia; Deutsche Forschungsgemeinschaft; Grupo Ferrer Internacional, S.A The EXPERT registry was funded by Bayer AG (Berlin, Germany) and Merck Sharp & Dohme Corp., a subsidiary of Merck & Co. Inc., Kenilworth, NJ, USA. The authors acknowledge the database administration by Torsten Tille, Dresden, and the project administration of Mrs Romy Hoppenz and Mrs Linda Kottke at GWT-TUD GmbH, Dresden. Medical writing services provided by Richard Murphy PhD of Adelphi Communications Ltd, Macclesfield, UK were funded by Bayer AG in accordance with Good Publication Practice (GPP3) guidelines. The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Prof Marius M. Hoeper reports personal fees from Bayer AG, during the conduct of the study; personal fees from Actelion, personal fees from Acceleron, personal fees from MSD, personal fees from Jansen, personal fees from Pfizer, outside the submitted work. Dr Hans Klose reports speaker and consultancy fees from Actelion, Bayer AG, GSK, Novartis, Pfizer, and United Therapeutics and research support from Actelion, Bayer AG, GSK, Pfizer, and MSD. Dr Michael Halank reports personal fees and non-financial support from Actelion, AstraZeneca, Bayer AG, Berlin-Chemie, GSK, OMT, MSD, and Novartis. Dr George Giannakoulas reports speaker and consultancy fees from Actelion, Bayer, ELPEN Pharmaceuticals, GSK, Pfizer, Lilly, and United Therapeutics, and research support from GSK, ELPEN Pharmaceuticals, and Galenica. Dr Henning Gall has received honoraria and/or other support from Actelion, AstraZeneca, Bayer, BMS, GSK, Janssen-Cilag, Lilly, MSD, Novartis, OMT, Pfizer, and United Therapeutics. Dr Pavel Jansa reports consultancy and speaker fees from MSD, AOP Orphan, and Actelion. Prof Ekkehard Grünig reports research grants and speaker honoraria/consultancy fees from Actelion and Bayer/MSD, research grants from GSK, United Therapeutics, Bellerophon, OMT GmbH, Pfizer, Reata, and Novartis, and speaker honoraria from Bial, Medscape, and OrPha Swiss GmbH. Prof David Pittrow reports personal fees from Actelion, Bayer AG, Aspen, Boehringer Ingelheim, Sanofi, Biogen, Shire, and MSD outside the submitted work. Silvia Ulrich reports research grants and personal fees from Actelion, Bayer, MSD, and Orpha Swiss. Tobias J. Lange has received personal fees from Actelion, MSD, Pfizer, and OMT orphan. Dr Iraklis Tsangaris reports speaker and consultancy fees from Actelion, Bayer AG, ELPEN, GSK, MSD, Pfizer, and United Therapeutics. Stephan Rosenkranz reports remunerations for lectures and/or consultancy from Abbott, Actelion, Arena, Bayer, Ferrer, GSK, MSD, Novartis, Pfizer, and United Therapeutics; and research support to his institution from Actelion, Bayer, Novartis, Pfizer, and United Therapeutics. Repke J. Snijder reports grants from Pfizer and Actelion Pharmaceuticals. Prof Iveta Šimková reports consultancy and speaker fees from MSD, AOP Orphan, and Actelion. Dr Marc Humbert reports grants and personal fees from Bayer and GSK, and personal fees from Actelion, Merck, and United Therapeutics. Marion Delcroix has received investigator, speaker, consultant, and steering committee member fees from Actelion, Bayer AG, Bellerophon, Eli Lilly, GlaxoSmithKline, MSD, Pfizer, and Reata, and research grants from Actelion. Joan A. Barberà reports receipt of honoraria for consultation or speaker fees from Actelion and Merck; and research support through his institution from Actelion, Merck, GlaxoSmithKline, and Ferrer. Joanna Pepke-Zaba reports research grants and speaker honoraria/consultancy fees from Actelion, Bayer/MSD, and GSK. Jean-Luc Vachiéry reports ongoing consultancies to Actelion, Sonnivie, Arena Pharma, Bial Portela, and Respira Therapeutics, past consultancies to AstraZeneca, BayerShering, CardioMEMS, GlaxoSmithKline, Pfizer, Merck, and United Therapeutics, and current membership of an advisory board or similar group for Actelion and GlaxoSmithKline. Jean-Luc Vachiéry's institution receives funding from Actelion Pharmaceuticals for performing clinical studies. Regina Steringer-Mascherbauer, Jens Klotsche, and Miguel-Angel Gomez Sanchez have no conflicts of interest relevant to the EXPERT study. Hossein-Ardeschir Ghofrani reports personal fees for advisory board work, and payment for lectures including service on speaker bureaus, from Actelion, Bayer, GSK, Novartis, and Pfizer; consultancy fees from Actelion, Bayer, Bellerophon Pulse Technologies, GSK, MSD, Novartis, and Pfizer; and grants from Deutsche Forschungsgemeinschaft (DFG). Pilar Escribano Subias reports personal fees from Actelion, Bayer AG, GlaxoSmithKline, and Merck Sharp & Dohme, and grants from Actelion, Bayer AG, GlaxoSmithKline, and Ferrer, outside the submitted work. Gérald Simonneau reports personal fees and non-financial support from Actelion, personal fees and non-financial support from Bayer, personal fees and non-financial support from MSD, outside the submitted work. Douglas S. Helmersen reports industry-sponsored research with Bayer AG, United Therapeutics, and Gilead Sciences, Inc., and advisory board/speaker fees from Bayer AG and Actelion. David Langleben reports honoraria, consultation fees, research support, and/or travel expenses from Actelion, Arena, Bayer AG, Northern Therapeutics, PhaseBio, Acceleron, Janssen, and United Therapeutics. Anco Boonstra reports consultancy fees from Pfizer BV and hospitality from Teva Nederland. Lisa M. Mielniczuk reports speaker fees and honoraria from Bayer AG, and speaker fees, consultancy fees, and travel fees from Actelion. Evgenia Williams and Christian Meier are employees of Bayer AG.
Published: 2021
Full Text: View/download PDF

9. Predictive value of plasma copeptin level for diagnosis and mortality of pulmonary embolism

Author: Onur Sinan Deveci, Ali Deniz, Caglar Emre Cagliyan, Ismail Hanta, Ayhan Usal, Muhammet Bugra Karaaslan, Oya Baydar, Caglar Ozmen, and Anil Akray
Subjects: medicine.medical_specialty, Medicine (General), Embolia pulmonar/diagnóstico, Hemodynamics, Arginine vasopressin/metabolism, 030204 cardiovascular system & hematology, 03 medical and health sciences, Plasma, 0302 clinical medicine, Copeptin, R5-920, Disease severity, Predictive Value of Tests, Internal medicine, medicine, Humans, 030212 general & internal medicine, Arginina vasopressina/metabolism, business.industry, Morte, Glycopeptides, Copeptin Measurement, General Medicine, medicine.disease, Prognosis, Predictive value, Pulmonary embolism, Death, Biomarcadores, Predictive value of tests, Acute Disease, Cardiology, Biomarker (medicine), Embolia pulmonar/mortalidade, Pulmonary embolism/mortality, business, Pulmonary Embolism, Biomarkers, Pulmonary embolism/diagnosis
Abstract: SUMMARY OBJECTIVE: Early diagnosis and risk stratification may provide a better prognosis in pulmonary embolism (PE). Copeptin has emerged as a valuable predictive biomarker in various cardiovascular diseases. The aim of this study was to determine the levels of copeptin in patients with acute PE and to evaluate its relationship with disease severity and PE-related death. METHODS: Fifty-four patients and 60 healthy individuals were included in this study. Copeptin concentrations and right ventricular dysfunction were analyzed. The correlation between copeptin levels and hemodynamic and echocardiographic parameters was examined. After these first measurements, patients were evaluated with PE-related mortality at the one-year follow-up. RESULTS: The copeptin levels were higher in PE patients than in the control group (8.3 ng/mL vs 3.8 ng/mL, p
Published: 2020

10. COPD

Author: Michael Studnicka, Andreas Horner, Lea Sator, A. Sonia Buist, Bernd Lamprecht, NanShan Zhong, Shengming Liu, Jiachun Lu, Pixin Ran, Dali Wang, Jingping Zheng, Yumin Zhou, Ali Kocabaş, Attila Hancioglu, Ismail Hanta, Sedat Kuleci, Ahmet Sinan Turkyilmaz, Sema Umut, Turgay Unalan, Torkil Dawes, Eric Bateman, Anamika Jithoo, Desiree Adams, Edward Barnes, Jasper Freeman, Anton Hayes, Sipho Hlengwa, Christine Johannisen, Mariana Koopman, Innocentia Louw, Ina Ludick, Alta Olckers, Johanna Ryck, Janita Storbeck, Thorarinn Gislason, Bryndis Benedikdtsdottir, Kristin Jörundsdottir, Lovisa Gudmundsdottir, Sigrun Gudmundsdottir, Gunnar Gundmundsson, Ewa Nizankowska-Mogilnicka, Jakub Frey, Rafal Harat, Filip Mejza, Pawel Nastalek, Andrzej Pajak, Wojciech Skucha, Andrzej Szczeklik, Magda Twardowska, Tobias Welte, Isabelle Bodemann, Henning Geldmacher, Alexandra Schweda-Linow, Amund Gulsvik, Tina Endresen, Lene Svendsen, Wan C. Tan, Wen Wang, David M. Mannino, John Cain, Rebecca Copeland, Dana Hazen, Jennifer Methvin, Renato B. Dantes, Lourdes Amarillo, Lakan U. Berratio, Lenora C. Fernandez, Norberto A. Francisco, Gerard S. Garcia, Teresita S. de Guia, Luisito F. Idolor, Sullian S. Naval, Thessa Reyes, Camilo C. Roa, Ma. Flordeliza Sanchez, Leander P. Simpao, Christine Jenkins, Guy Marks, Tessa Bird, Paola Espinel, Kate Hardaker, Brett Toelle, Peter G.J. Burney, Caron Amor, James Potts, Michael Tumilty, Fiona McLean, E.F.M. Wouters, G.J. Wesseling, Cristina Bárbara, Fátima Rodrigues, Hermínia Dias, João Cardoso, João Almeida, Maria João Matos, Paula Simão, Moutinho Santos, Reis Ferreira, Christer Janson, Inga Sif Olafsdottir, Katarina Nisser, Ulrike Spetz-Nyström, Gunilla Hägg, Gun-Marie Lund, Rain Jõgi, Hendrik Laja, Katrin Ulst, Vappu Zobel, Toomas-Julius Lill, Parvaiz A. Koul, Sajjad Malik, Nissar A. Hakim, Umar Hafiz Khan, Rohini Chowgule, Vasant Shetye, Jonelle Raphael, Rosel Almeda, Mahesh Tawde, Rafiq Tadvi, Sunil Katkar, Milind Kadam, Rupesh Dhanawade, Umesh Ghurup, Imed Harrabi, Myriam Denguezli, Zouhair Tabka, Hager Daldoul, Zaki Boukheroufa, Firas Chouikha, Wahbi Belhaj Khalifa, Fernando G. Ayuyao, Cecil Z. Tady, Daniel T. Tan, Sylvia Banal-Yang, Vincent M. Balanag, Maria Teresita N. Reyes, Renato. B. Dantes, Sanjay Juvekar, Siddhi Hirve, Somnath Sambhudas, Bharat Chaidhary, Meera Tambe, Savita Pingale, Arati Umap, Archana Umap, Nitin Shelar, Sampada Devchakke, Sharda Chaudhary, Suvarna Bondre, Savita Walke, Ashleshsa Gawhane, Anil Sapkal, Rupali Argade, Vijay Gaikwad, Sundeep Salvi, Bill Brashier, Jyoti Londhe, Sapna Madas, Daniel Obaseki, Gregory Erhabor, Olayemi Awopeju, and Olufemi Adewole
Subjects: Pulmonary and Respiratory Medicine, Spirometry, medicine.medical_specialty, COPD, medicine.diagnostic_test, business.industry, MEDLINE, Pulmonary disease, Critical Care and Intensive Care Medicine, medicine.disease, medicine, Cardiology and Cardiovascular Medicine, Intensive care medicine, business
Published: 2020
Full Text: View/download PDF

11. Pulmonary MALT lymphoma with underlying interstitial lung disease: A case report and rewiev of the literature

Author: Serkan Gokcay, Melek Ergin, Semra Paydas, Ismail Hanta, Mahmut Büyükşimşek, Cem Mirili, Emine Bağır Kılıç, Ali Ogul, Evren Yetisir, and Isa Burak Guney
Subjects: Pathology, medicine.medical_specialty, Lung, medicine.diagnostic_test, business.industry, Marginal zone lymphoma, Interstitial lung disease, MALT lymphoma, Low grade lymphoma, respiratory system, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, medicine.disease, lcsh:RC254-282, respiratory tract diseases, medicine.anatomical_structure, Oncology, immune system diseases, hemic and lymphatic diseases, Biopsy, medicine, Differential diagnosis, business, Wedge resection (lung)
Abstract: Marginal zone lymphoma (MZL) is low grade lymphoma and accounts about 5% of all lymphomas and 5–10% of MZLs are localized in the lung. Interstitial Lung Disease (ILD) is a group of systemic diseases characterized by diffuse inflammation in lung and there is a long list for differential diagnosis. Here we represent a 53 years old man who had been followed as ILD by the department of chest diseases for 1,5 years. Biopsy taken by wedge resection was reported as MZL. Keywords: Non-Hodgkin lymphoma, Interstitial lung disease, MALT lymphoma
Published: 2018
Full Text: View/download PDF

12. Airflow Obstruction and Use of Solid Fuels for Cooking or Heating BOLD (Burden of Obstructive Lung Disease) Results

Author: André F. S. Amaral, Jaymini Patel, Bernet S. Kato, Daniel O. Obaseki, Hervé Lawin, Wan C. Tan, Sanjay K. Juvekar, Imed Harrabi, Michael Studnicka, Emiel F. M. Wouters, Li-Cher Loh, Eric D. Bateman, Kevin Mortimer, A. Sonia Buist, Peter G. J. Burney, NanShan Zhong, Shengming Liu, Jiachun Lu, Pixin Ran, Dali Wang, Jingping Zheng, Yumin Zhou, Ali Kocabaş, Attila Hancioglu, Ismail Hanta, Sedat Kuleci, Ahmet Sinan Turkyilmaz, Sema Umut, Turgay Unalan, Torkil Dawes, Bernd Lamprecht, Lea Schirhofer, Eric Bateman, Anamika Jithoo, Desiree Adams, Edward Barnes, Jasper Freeman, Anton Hayes, Sipho Hlengwa, Christine Johannisen, Mariana Koopman, Innocentia Louw, Ina Ludick, Alta Olckers, Johanna Ryck, Janita Storbeck, Thorarinn Gislason, Bryndis Benedikdtsdottir, Kristin Jörundsdottir, Lovisa Gudmundsdottir, Sigrun Gudmundsdottir, Gunnar Gundmundsson, Ewa Nizankowska-Mogilnicka, Jakub Frey, Rafal Harat, Filip Mejza, Pawel Nastalek, Andrzej Pajak, Wojciech Skucha, Andrzej Szczeklik, Magda Twardowska, Tobias Welte, Isabelle Bodemann, Henning Geldmacher, Alexandra Schweda-Linow, Amund Gulsvik, Tina Endresen, Lene Svendsen, Wen Wang, David M. Mannino, John Cain, Rebecca Copeland, Dana Hazen, Jennifer Methvin, Renato B. Dantes, Lourdes Amarillo, Lakan U. Berratio, Lenora C. Fernandez, Norberto A. Francisco, Gerard S. Garcia, Teresita S. de Guia, Luisito F. Idolor, Sullian S. Naval, Thessa Reyes, Camilo C. Roa, Ma. Flordeliza Sanchez, Leander P. Simpao, Christine Jenkins, Guy Marks, Tessa Bird, Paola Espinel, Kate Hardaker, Brett Toelle, Peter GJ Burney, Caron Amor, James Potts, Michael Tumilty, Fiona McLean, E. F. M. Wouters, G. J. Wesseling, Cristina Bárbara, Fátima Rodrigues, Hermínia Dias, João Cardoso, João Almeida, Maria João Matos, Paula Simão, Moutinho Santos, Reis Ferreira, Christer Janson, Inga Sif Olafsdottir, Katarina Nisser, Ulrike Spetz-Nyström, Gunilla Hägg, Gun-Marie Lund, Rain Jõgi, Hendrik Laja, Katrin Ulst, Vappu Zobel, Toomas-Julius Lill, Parvaiz A Koul, Sajjad Malik, Nissar A Hakim, Umar Hafiz Khan, Rohini Chowgule, Vasant Shetye, Jonelle Raphael, Rosel Almeda, Mahesh Tawde, Rafiq Tadvi, Sunil Katkar, Milind Kadam, Rupesh Dhanawade, Umesh Ghurup, Myriam Denguezli, Zouhair Tabka, Hager Daldoul, Zaki Boukheroufa, Firas Chouikha, Wahbi Belhaj Khalifa, Fernando G. Ayuyao, Cecil Z. Tady, Daniel T. Tan, Sylvia Banal-Yang, Vincent M. Balanag, Maria Teresita N. Reyes, Renato. B. Dantes, Sanjay Juvekar, Siddhi Hirve, Somnath Sambhudas, Bharat Chaidhary, Meera Tambe, Savita Pingale, Arati Umap, Archana Umap, Nitin Shelar, Sampada Devchakke, Sharda Chaudhary, Suvarna Bondre, Savita Walke, Ashleshsa Gawhane, Anil Sapkal, Rupali Argade, Vijay Gaikwad, Sundeep Salvi, Bill Brashier, Jyoti Londhe, Sapna Madas, Mohamed C Benjelloun, Chakib Nejjari, Mohamed Elbiaze, Karima El Rhazi, Daniel Obaseki, Gregory Erhabor, Olayemi Awopeju, Olufemi Adewole, M. Al Ghobain, H. Alorainy, E. El-Hamad, M. Al Hajjaj, H. Ayan, D. Rowena, F. Rofel, E. Elizabeth, I. Imelda, H. Safia, null Lyla, Talant M. Sooronbaev, Bermet M. Estebesova, Meerim Akmatalieva, Saadat Usenbaeva, Jypara Kydyrova, Eliza Bostonova, Ulan Sheraliev, Nuridin Marajapov, Nurgul Toktogulova, Berik Emilov, Toktogul Azilova, Gulnara Beishekeeva, Nasyikat Dononbaeva, null AijamalTabyshova, Wezzie Nyapigoti, Ernest Mwangoka, Mayamiko Kambwili, Martha Chipeta, Gloria Banda, Suzgo Mkandawire, Justice Banda, Asma Elsony, Hana A. Elsadig, Nada Bakery Osman, Bandar Salah Noory, Monjda Awad Mohamed, Hasab Alrasoul Akasha Ahmed Osman, Namarig Moham ed Elhassan, Abdel Mu‘is El Zain, Marwa Mohamed Mohamaden, Suhaiba Khalifa, Mahmoud Elhadi, Mohand Hassan, Dalia Abdelmonam, Hasan Hafizi, Anila Aliko, Donika Bardhi, Holta Tafa, Natasha Thanasi, Arian Mezini, Alma Teferici, Dafina Todri, Jolanda Nikolla, Rezarta Kazasi, Hamid Hacene Cherkaski, Amira Bengrait, Tabarek Haddad, Ibtissem Zgaoula, Maamar Ghit, Abdelhamid Roubhia, Soumaya Boudra, Feryal Atoui, Randa Yakoubi, Rachid Benali, Abdelghani Bencheikh, Nadia Ait-Khaled, Akramul Islam, Syed Masud Ahmed, Shayla Islam, Qazi Shafayetul Islam, null Mesbah-Ul-Haque, Tridib Roy Chowdhury, Sukantha Kumar Chatterjee, Dulal Mia, Shyamal Chandra Das, Mizanur Rahman, Nazrul Islam, Shahaz Uddin, Nurul Islam, Luiza Khatun, Monira Parvin, Abdul Awal Khan, Maidul Islam, Abdul Rashid, Siti Sholehah, Herve Lawin, Arsene Kpangon, Karl Kpossou, Gildas Agodokpessi, Paul Ayelo, Benjamin Fayomi, Pulmonologie, MUMC+: MA Longziekten (3), and RS: NUTRIM - R3 - Respiratory & Age-related Health
Subjects: Pulmonary and Respiratory Medicine, medicine.medical_specialty, Chronic bronchitis, solid fuels (biomass), Pulmonary disease, Biomass smoke, urologic and male genital diseases, Critical Care and Intensive Care Medicine, Airflow obstruction, airflow obstruction, Lower limit, chronic obstructive pulmonary disease, LOWER LIMIT, 03 medical and health sciences, 0302 clinical medicine, BIOMASS SMOKE, POLLUTION, low-income countries, Internal medicine, YOUNG-ADULTS, PULMONARY-DISEASE, Medicine, 030212 general & internal medicine, CHIMNEY STOVE INTERVENTION, COPD, business.industry, Original Articles, medicine.disease, Solid fuel, REFERENCE VALUES, respiratory tract diseases, CHRONIC-BRONCHITIS, 030228 respiratory system, NEVER-SMOKERS, Reference values, Cardiology, RISK-FACTORS, business
Abstract: Rationale: Evidence supporting the association of chronic obstructive pulmonary disease or airflow obstruction with use of solid fuels is conflicting and inconsistent. Objectives: To assess the association of airflow obstruction with self-reported use of solid fuels for cooking or heating. Methods: We analyzed 18,554 adults from the BOLD (Burden of Obstructive Lung Disease) study, who had provided acceptable post-bronchodilator spirometry measurements, and information on use of solid fuels. The association of airflow obstruction with use of solid fuels for cooking or heating was assessed by sex, within each site, using regression analysis. Estimates were stratified by national income and meta-analyzed. We performed similar analyses for spirometric restriction, chronic cough, and chronic phlegm. Measurements and Main Results: We found no association between airflow obstruction and use of solid fuels for cooking or heating (odds ratio [OR] for men, 1.20 [95% confidence interval (CI), 0.94–1.53]; OR for women, 0.88 [95% CI, 0.67–1.15]). This was true for low-/middle- and high-income sites. Among never-smokers, there was also no evidence of an association of airflow obstruction with use of solid fuels (OR for men, 1.00 [95% CI, 0.57–1.76]; OR for women, 1.00 [95% CI, 0.76–1.32]). Overall, we found no association of spirometric restriction, chronic cough, or chronic phlegm with the use of solid fuels. However, we found that chronic phlegm was more likely to be reported among female never-smokers and those who had been exposed for 20 years or longer. Conclusions: Airflow obstruction assessed from post-bronchodilator spirometry was not associated with use of solid fuels for cooking or heating.
Published: 2018
Full Text: View/download PDF

13. Benralizumab for the Prevention of COPD Exacerbations

Author: Criner, G. J., Celli, B. R., Brightling, C. E., Agusti, A., Papi, A., Singh, D., Sin, D. D., Vogelmeier, C. F., Sciurba, F. C., Bafadhel, M., Backer, V., Kato, M., Ramirez-Venegas, A., Wei, Y. -F., Bjermer, L., Shih, V. H., Jison, M., O'Quinn, S., Makulova, N., Newbold, P., Goldman, M., Martin, U. J., GALATHEA Study Investigators, TERRANOVA Study Investigators, Otto, Burghuber, Bernhard, Forstner, Gerhard, Köberl, Bernd, Lamprecht, Judith, Löffler-Ragg, Horst, Olschewski, Michael, Studnicka, Francois, Beaucage, Guy, Chouinard, Anthony, Dechant, Anthony, Dowell, Jacques, Hebert, Sohail, Khattak, Kieran, Killian, William, Killorn, Andy, Lam, Francois, Maltais, Darcy, Marciniuk, Lyle, Melenka, Bonavuth, Pek, Jeremy, Road, Donald, Sin, Alain, Vaugeois, Brandie, Walker, Tomas, Dvorak, Stanislav, Holub, Otakar, Hokynar, Vitezslav, Kolek, Daniela, Kopecka, Jan, Krepelka, Jaroslav, Mares, Josef, Veverka, Vladimir, Zindr, Sabine, Ballenberger, Rolf, Dichmann, Christian, Geßner, Margret, Jandl, Claus, Keller, Joachim, Kirschner, Marc, Kornmann, Petra, Mikloweit, Ingomar, Naudts, Axel, Overlack, Isabelle, Schenkenberger, Volker, Schlegel, Lutz Von Versen, Claus Franz Vogelmeier, Stefan, Zielen, István, Albert, Beatrix, Bálint, Mária Csilla Hangonyi, Teréz, Kecskés, Anikó, Kurucz, Balázs, Medgyasszay, Lajos, Molnár, János, Mucsi, Márta, Papp, Magdolna, Póczi, Éva, Radeczky, Zsolt Pápai Székely, Csilla, Szabó, Gyöngyi, Szabó, Melinda, Szabó, Alfredo Antonio Chetta, Giuseppe Di Maria, Giulio, Donazzan, Federica, Meloni, Elisabetta, Pace, Pierluigi, Paggiaro, Alberto, Papi, Ricciardolo, Fabio Luigi Massimo, Antonio, Spanevello, Fumiaki, Aoki, Ryosuke, Eda, Takeo, Endo, Yasushi, Fukushima, Kenichi, Gemba, Naoki, Hagimoto, Hiromasa, Harada, Yasuko, Harada, Norihiko, Hata, Osamu, Hataji, Nobuo, Hatakeyama, Takahiko, Horiguchi, Gen, Ideura, Motoyasu, Iikura, Azusa, Ikegami, Shirou, Imokawa, Yoshikazu, Inoue, Takeshi, Isobe, Ryoji, Ito, Susumu, Iwata, Tadashi, Kamei, Motokazu, Kato, Hideki, Katsura, Yuji, Kawarada, Norio, Kihara, Masaharu, Kinoshita, Takashi, Kinoshita, Tomoo, Kishaba, Hideo, Kita, Arihiro, Kiyosue, Shigeru, Komatsu, Kazuki, Konishi, Sekiya, Koyama, Makoto, Kudo, Kazuhiko, Machida, Hironi, Makita, Hiroto, Matsuse, Naoki, Miyazawa, Hiroyuki, Nakamura, Yuji, Nakatani, Kazuyuki, Nishimura, Takashi, Nishimura, Junichi, Ogawa, Hiroyuki, Ohbayashi, Tetsuro, Ohdaira, Tsukasa, Ohnishi, Kazuhiko, Oki, Masahiko, Saito, Kenji, Sakamoto, Osamu, Sakamoto, Hisakuni, Sekino, Noriharu, Shijubo, Masaharu, Shinkai, Hideo, Soto, Yoshitaka, Sugawara, Noriaki, Suko, Hisaho, Takahashi, Masamitsu, Takahashi, Tsuneyuki, Takahashi, Hiroshi, Tanaka, Hiroyuki, Taniguchi, Tadayuki, Terada, Takao, Tochigi, Kazuyo, Tohyama, Hirokazu, Tokuyasu, Keisuke, Tomii, Tomomasa, Tsuboi, Mitsuyoshi, Utsugi, Katsumaru, Yamamoto, Michiko, Yamamoto, Shuichi, Yano, Makoto, Yoshida, Frank, Custers, Richard, Dekhuijzen, Remco, Djamin, Jan Willem Van Dan Berg, Lowie, Vanfleteren, Pascal, Wielders, Bogusława, Cimoszko, Anna, Doboszyńska, Andrzej, Dyczek, Andrzej, Fal, Krystyna, Folcik, Łukasz, Goliński, Marek, Jutel, Andrzej, Kolczyński, Piotr, Kuna, Ewa, Łączyńska, Wojciech, Machowiak, Maciej, Marczak, Joanna, Markiewicz, Janusz, Milanowski, Grzegorz, Mincewicz, Maria, Nittner-Marszalska, Wojciech, Papiewski, Małgorzata, Pawlukiewicz, Witold, Pomiećko, Barbara, Rewerska, Cezary, Rybacki, Wojciech, Skucha, Ewa, Trębas-Pietraś, Ewa, Uhryn, Małgorzata, Żurowska-Gębala, Laurentia, Andrei, Traian, Mihaescu, Stefan, Mihaicuta, Eniko Vera Pall, Ioan, Petrui, Angelica, Savu, Claudia, Toma, Ana, Trailescu, Vladimir, Abrosimov, Nataliya, Astafyeva, Evgenyi, Bazdyrev, Nadezhda, Berdnikova, Laura, Bolieva, Ekaterina, Bukreeva, Valery, Chistyakov, Anna, Galustyan, Halida, Gantseva, Svetlana, Goncharova, Sergey, Grigoriev, Galina, Ignatova, Inna, Ilyashevich, Nadezhda, Izmozherova, Magomed, Kamalov, Yaroslava, Khovaeva, Natalia, Kuzubova, Lyudmila, Kvitkova, Liudmila, Lenskaya, Igor, Leshchenko, Olga, Magnitskaya, Boris, Molotilov, Artem, Molotkov, Svetlana, Myasoedova, Sergey, Nedogoda, Vladimir, Nosov, Marina, Osipenko, Andrey, Peskov, Veronika, Popova, Oksana, Ratushnay, Irina, Ryzhova, Olga, Shangina, Natalia, Shaporova, Evgeny, Shmelev, Lybov, Shpagina, Alexander, Shutkin, Yuri, Shvarts, Mikhail, Smirnov, Irina, Stitsenko, Maksim, Vasilev, Arkadiy, Vertkin, Elena, Vishneva, Alexander, Vizel, Anna, Zateyschikova, Mohamed, Abdool-Gaffar, Ismail, Abdullah, Axel, Bruning, Nyda, Fourie, Michael, Greenblatt, Mohammed, Tayob, Venter, K, An Soo Jang, Kwan Ho Lee, Sang Haak Lee, Sook Young Lee, Suk Joong Yong, Kwang Ha Yoo, Soo Taek Uh, Ramón Agüero Balbín, David Ramos Barbón, Álvar Agustí García-Navarro, José Luis Velasco Garrido, Sergi Pascual Guardia, Eduard Monso Molas, Luis De Teresa Parreño, Borja García-Cosio Piqueras, German Peces-Barba Romero, Myriam Calle Rubio, Fernando Sánchez-Toril López, Alicia Marín Tapia, Heidi Martin Braschler, Martin, Brutsche, Michael, Grob, Jörg, Leuppi, Daiana, Stolz, Alexander, Turk, Nawar, Bakerley, Mona, Bafadhel, Christopher, Brightling, Rekha, Chaudhuri, Gourab, Choudhury, Graham, Devereux, Imran, Hussain, Kai, Lee, William, Macnee, Ravindran, Mahadeva, Matthew, Masoli, Monica, Nordstrom, Manish, Patel, Allan, Reid, Dinesh, Saralaya, Tariq, Sethi, Sukh Dave Singh, Anthony, G de Soyza, Tom, Wilkinson, Alice, Turner, Helen, Ward, Chandar, Abboy, Ivan, Ackerman, Idalia, Acosta, Arun, Adlakha, Bassil, Aish, Mohamed, Ali, Charles, Andrews, Robby, Ayoub, Anil, Badhwar, Dennis, Bassetti, Sherif El Bayadi, Richard, Beasley, Shashi, Bellam, Jonathan, Bernstein, Maria, Blahey, Scott, Bloom, Eugene, Bleecker, Wesley, Bray, Johnathan, Brewer, Robert, Buynak, William, Calhoun, Edward, Campbell, Anthony, Captain, Birjis, Chinoy, Kenneth, Chinsky, Geoffrey, Chupp, Arsenio, Columbie, Clinton, Corder, Gerard, Criner, Humberto, Cruz, Edward, Cullen, Kevin, Deboer, Michael, Denenberg, Mark, Dransfield, Leonard, Dunn, Miles, Elmore, David, Erb, Faisal, Fakih, Gary, Ferguson, Charles, Fogarty, Mark, Freed, Stephen, Fritz, David, Fuentes, Shariar, Cohen-Gadol, Robert, Garver, John, Given, Luis Ramos Gonez, Raul Ebran Gonzalez, Robert, Gordon, Gregory, Gottschlich, Donald, Graham, David, Grant, Gary, Greenwald, James, Greenwald, Kenneth, Haft, Gregory, Hammond, Nadia, Hansel, Jeffrey, Harris, Humberto, Hernandez, Marvin, Heuer, Albrecht, Heyder, David, Hill, Willis, Holloway, Octavian, Ioachimescu, Richard, Jackson, Ajay, Jain, Nan, Jiang, Thomas, Kaelin, Adolfo, Kaplan, Mitchell, Kaye, Akram, Khan, Yekaterina, Khronusova, Ryan, Klein, Joel, Kline, Firas, Koura, Ritsu, Kuno, Ware, Kuschner, Jean Claude Labissiere, David Laman Jr, John, Lee, Mitchell, Lee, Lawrence, Levinson, Njira, Lugogo, Mador, M, Nathaniel, Marchetti, Rafael, Martinez, Richard, Martinez, Peter, Mattar, David, Maybee, Dennis, Mcgraw, Michael, Mcguire, Curtis, Mello, Aaron, Milstone, John, Mitchell, Wendy, Moore, Timothy, Moriarty, Cheta, Nand, Brooke, Nevins, Ikeadi, Ndukwu, Rachel, Nisbet, David, Nyanjom, Maria, Nualart, Thomas, O'Brien, Mikhail, Palatnik, Gnyandev, Patel, Amit, Patel, Guido, Perez, Christopher, Perry, Michael, Pfeffer, Krishna, Pudi, Marina, Raikhel, Murali, Ramaswamy, Joe, Ramsdell, Donato, Ricci, Gary, Richmond, Eugene, Ryan, Fadi, Saba, Boris, Sagalovich, C Andrew Schroeder, Timothy, Scialla, Frank, Sciurba, Amit, Shah, Nirav, Shah, Zeeshan, Shaikh, Akhtar, Siddiqui, Barry, Sigal, Thomas, Siler, Howard, Silverboard, William, Sims, Clyde, Southwell, Selwyn, Spangenthal, Peruvemba, Sriram, James, Stocks, Tony, Su, John, Suen, Robert, Sussman, Horia, Tatu, Antonio, Terrelonge, Alan, Thomas, Mario, Torres, Rodolfo, Trejo, Miguel, Trevino, Banks, Turner, Manuel, Villareal, Janine, Vintch, Neal, Warshoff, Jan, Westerman, Philip, Wexler, Thomas, Yunger, Amir, Zeki, Mariano Fernandez Acquier, Norma, Aramayo, German, Arce, Juan, Belloni, Víctor, Cambursano, Carlos De La Vega, Fernando Rodriguez Chariarse, Pedro, Elias, Marcelo, Fernández, Ana, Lopez, Andrea, Medina, María, Otaola, Maria Salazan Saez, Maria De Salvo, Fernando, Scherbovsky, Ana, Stok, Jorge, Taborda, Alberto, Tolcachier, Fernando, Verra, Carlos, Victorio, Rita Gisela Delgado Vizcarra, Philip, Bardin, Peter, Bremner, Martin, Phillips, John, Upham, Peter, Wark, Antoine, Bolly, Alain, Delobbe, Peter, Driesen, Eduard, Janssens, Wim, Janssens, Olivier, Michel, Bernard, Vandooren, Martti, Antila, Jussara, Fiterman, Carlos, Fritscher, Jorge, Hetzel, Jose, Jardim, Waldo De Mattos, Rafael, Martins, Maria Eunice De Oliveira, Andreia, Pez, Maria, Sales, Rafael, Stelmach, Priscila, Wolff, Svetla, Andreeva, Reneta, Antonova, Ana, Dancheva, Yuliya, Ivanova, Slavcho, Ivanov, Hristo, Metev, Iveta, Naydenova, Tatyana, Petkova, Galina, Petrova, Kostadinka, Sotirova, Mariyana, Stoyanova, Rumen, Tiholov, Iliyana, Valkanova, Oleg, Yakov, Rosa, Feijoo, Juana, Pavie, Patricia, Schönffeldt, Absalon, Silva, Victor, Martinez, David, Espinosa, Alejandro, Londono, Dora, Molina, Gonzalo, Prada, Andrés, Rico, Gregorio Sanchez Vallejo, Alvaro, Urbina, Ana, Vanegas, Maria, Villegas, Josip, Aralica, Gordana, Stjepanovic, Vibeke, Backer, Uffe, Bødtger, Christian, Meyer, Læge Sven Nielsen, Anders Loekke Ottesen, Ingrid, Titlestad, Nathalie, Bautin, Arnaud, Bourdin, Pascal, Chanez, Francis, Couturaud, Antoine, Cuvelier, Gilles, Devouassoux, Pierre-Olivier, Girodet, Jean-François, Muir, Jean-Louis, Pépin, Alain, Proust, Azzedine, Yaici, Yochai, Adir, Gershon, Fink, Zvi, Fridlender, Gabriel, Izbicki, Mordechai, Kramer, Yehuda, Schwartz, Juan Moreno Hoyos Abril, Ricardo Campos Cerda, Efraín Montaño Gonzalez, Ricardo Ramirez Terrones, Rodolfo Posadas Valay, Alejandra, Ramirez-Venegas, Paul, Dawkins, Syed, Hussain, Benedict, Brockway, John, Richmond, Colin, Helm, Catherina, Chang, Jørn, Ahlqvist, Terje, Tollåli, Tadeusz, Tomala, Socorro, Castro, William, Chavez, Octavio, Cubas, Rolando, Estrella, Efrain, Felix, Ronal, Gamarra, Alfredo, Guerreros, Alberto, Matsuno, Danilo, Salazar, Miguel, Tsukayama, Albert Albay Jr, Teresita, Aquino, Tito, Atienza, Joven Roque Gonong, Ronnie, Samoro, Joel, Santiaguel, Beata, Asankowicz-Bargiel, Ewa, Pisarczyk-Bogacka, Renata, Bijata-Bronisz, Marta, Chełmińska, Małgorzata, Dobryniewska, Anna, Olech-Cudzik, Tomasz, Fijołek, Krzysztof, Filipek, Agata, Kot, Bożena, Kucińska, Krzysztof, Lis, Elżbieta, Rybicka-Liszewska, Marzenna, Tarnowska-Matusiak, Robert, Mróz, Piotr, Napora, Wojciech, Naumnik, Artur, Niemiec, Władysław, Pierzchała, Grzegorz, Przybylski, Katarzyna, Styka, Danuta, Wrońska, Branislava, Milenkovic, Dobrivoje, Novkovic, Matijaz, Flezar, Niksa, Segota, Snezana Ulcar Kostic, Albert, Klobucar, Leif, Bjermer, Dan, Curiac, Christer, Janson, Pekka, Koskinen, Lundback, Bo, Åke, Olsson, Shih-Lung, Cheng, Ming-Lin, Ho, Jeng-Yuan, Hsu, Wu-Huei, Hsu, Ping-Hung, Kuo, Chin-Chou, Wang, Yu-Feng, Wei, Kuang-Yao, Yang, Watchara, Boonsawat, Somchai, Chantarothorn, Warangkana, Keeratichananont, Kittipong, Maneechotesuwan, Kanok, Pipatvech, Piamlarp, Sangsayunh, Sibel, Arinc, Sermin, Borekci, Arzu Kaner Erturk, Filiz, Kosar, Hakan, Gunen, Ismail, Hanta, Pinar Akin Kabalak, Tunc Alp Demir, Sibel, Nayci, Serir Aktogu Ozkan, Abdullah, Sayiner, Esra, Uzaslan, Viktor, Blazhko, Volodymyr, Gavrysyuk, Olena, Golub, Liudmyla, Iashyna, Tetiana, Ilashchuk, Volodymyr, Koshlia, Olena, Krakhmalova, Vitali, Kryvenko, Lesia, Kuryk, Olena, Levchenko, Yuriy, Mostovoy, Mykola, Ostrovskyy, Tetyana, Pertseva, Olena, Piura, Nadiya, Rudnytska, Ganna, Stupnytska, Nataliia, Velychko, Oleh, Yakovenko, Lilia Rodriguez Ables, Roger, Abrahams, Jose, Alvarez, Fernando, Arencibia, Chander, Arora, Samir, Arora, Francis, Averill, Kwabena, Ayesu, Stephen, Basheda, Steven, Bauer, Jose, Bautista, Matthew, Beacom, Hernando, Bernal, Subodh, Bhuchar, J'Cinda, Bitters, John, Burk, Elizabeth, Burkett, James, Cain, Robert, Call, Christopher, Chappel, Bartolome, Celli, Tom, Christensen, Jeremy, Cole, Jerome, Daniel, Nguyen, Dang, Enrique, Davis, Samuel, Deleon, Robert, Deluca, Ernesto, Diaz, Anthony, Dimarco, Calvin, Dixon, Ankur, Doshi, Hugh, Durrence, Alain, Eid, John, Elsen, Herbon, Fleming, May, Flores, Scott, Franczek, Gregory, Funk, Stuart, Garay, Bernard, Garcia, Joseph, Graif, Carl, Griffin, Yamirka Duardo Guerra, David, Headley, Mitzie, Hewitt, Susan, Hole, Robert, Holladay, Ira, Horowitz, Yu-Luen, Hsu, Jonathan, Ilowite, Stephen, Jones, Ravindra, Kashyap, Edward, Kerwin, Ahtaram, Khan, Nicole, Kimzey, James, Krainson, Flory, Kreutter, Kannappan, Krishnaswamy, Shahrukh, Kureishy, Albert, Lai, Alex, Lechin, Daria, Lee, Marcus, Lee, Williams, Leeds, Joseph, Lillo, Edward, Lisberg, Lawrence, Madoff, Narendra, Maheskwari, Mujibur, Majumder, Sashi, Makam, Douglas, Mapel, Matthew, Mardiney, Jennifer, Martin, Isaac, Melamed, Elvin, Mendez, Stuart, Millstone, Joseph, Montes, Lee, Morrow, Frank, Murphy, Dany, Obeid, France, Occy, Godson, Oguchi, Juan, Ortiz, Francisco, Padron, Ward, Paine, James, Pearle, Enrique, Pelayo, Vandely, Perez, David, Pham, Carlos, Piniella, Kevin, Pritchett, Padmashri, Rastogi, Stephen, Ryan, Syed, Rehman, Jackson, Rhudy, Eustace, Riley, James, Riser, Clifford, Risk, Emory, Robinette, Christopher, Roney, Gary, Ruoff, David, Russian, Mercedes, Samson, Jay, Sandberg, Jose, Santiago, William, Sargeant, Alan, Schecter, Jeffrey, Scott, Ilia, Segal, Sudhir, Sehgal, Frederic, Seifer, Sudhir, Sekhsaria, Richard, Sellman, Paul, Shapero, Jeffrey, Shea, Lawrence, Sher, John, Sibille, Jawed, Siddiqui, Toniya, Singh, Deren, Sinkowitz, Denise, Smyth, Daniel, Soteres, Daniel, Sousa, Ralph, Steele, Thomas, Stern, Jose, Suarez, Sever, Surdulescu, Ricardo, Tan, Tonny, Tanus, Raymond, Tidman, Aurelio, Torres-Consuegra, Barry, Troyan, John, Updegrove, Sanjay, Vadgama, Armando, Pineda-Velez, Eduardo, Viera, Andrew, Wachtel, Ralph, Wade, Jimin, Wang, Dave, Webster, Paul, Weinberg, Terry, Wells, Jeffrey, White, Bram, Wieskopf, Hugh, Windom, Patrick, Wright, David, Wyatt, Bassam, Yousef, Zahid, Zafar, Chau, Ngo, Huong, Le, Lan, Nguyen, Thanh, Nguyen, Nhung, Nguyen, SALAS, Danielle, Temple University [Philadelphia], Pennsylvania Commonwealth System of Higher Education (PCSHE), Harvard Medical School [Boston] (HMS), University of Leicester, University of Barcelona, Università degli Studi di Ferrara = University of Ferrara (UniFE), University of Manchester [Manchester], St. Paul’s Hospital - University of British Columbia [Vancouver, BC, Canada] (SPH-UBC), Philipps Universität Marburg = Philipps University of Marburg, University of Pittsburgh School of Medicine, University of Oxford, Bispebjerg University Hospital [Copenhagen, Denmark] (BUH), Kishiwada City Hospital [Osaka, Japan] (KCH), Instituto Nacional de Enfermedades Respiratorias [México, Mexico], I-Shou University [Kaohsiung, Taiwan] (ISU), Lund University [Lund], AstraZeneca [Gaithersburg, MD, USA] (AZ), Hypoxie et PhysioPathologie (HP2), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Grenoble Alpes (UGA), and Otto Burghuber, Bernhard Forstner, Gerhard Köberl, Bernd Lamprecht, Judith Löffler-Ragg, Horst Olschewski, Michael Studnicka, Francois Beaucage, Guy Chouinard, Anthony Dechant, Anthony Dowell, Jacques Hebert, Sohail Khattak, Kieran Killian, William Killorn, Andy Lam, Francois Maltais, Darcy Marciniuk, Lyle Melenka, Bonavuth Pek, Jeremy Road, Donald Sin, Alain Vaugeois, Brandie Walker, Tomas Dvorak, Stanislav Holub, Otakar Hokynar, Vitezslav Kolek, Daniela Kopecka, Jan Krepelka, Jaroslav Mares, Josef Veverka, Vladimir Zindr, Sabine Ballenberger, Rolf Dichmann, Christian Geßner, Margret Jandl, Claus Keller, Joachim Kirschner, Marc Kornmann, Petra Mikloweit, Ingomar Naudts, Axel Overlack, Isabelle Schenkenberger, Volker Schlegel, Lutz Von Versen, Claus Franz Vogelmeier, Stefan Zielen, István Albert, Beatrix Bálint, Mária Csilla Hangonyi, Teréz Kecskés, Anikó Kurucz, Balázs Medgyasszay, Lajos Molnár, János Mucsi, Márta Papp, Magdolna Póczi, Éva Radeczky, Zsolt Pápai Székely, Csilla Szabó, Gyöngyi Szabó, Melinda Szabó, Alfredo Antonio Chetta, Giuseppe Di Maria, Giulio Donazzan, Federica Meloni, Elisabetta Pace, Pierluigi Paggiaro, Alberto Papi, Fabio Luigi, Massimo Ricciardolo, Antonio Spanevello, Fumiaki Aoki, Ryosuke Eda, Takeo Endo, Yasushi Fukushima, Kenichi Gemba, Naoki Hagimoto, Hiromasa Harada, Yasuko Harada, Norihiko Hata, Osamu Hataji, Nobuo Hatakeyama, Takahiko Horiguchi, Gen Ideura, Motoyasu Iikura, Azusa Ikegami, Shirou Imokawa, Yoshikazu Inoue, Takeshi Isobe, Ryoji Ito, Susumu Iwata, Tadashi Kamei, Motokazu Kato, Hideki Katsura, Yuji Kawarada, Norio Kihara, Masaharu Kinoshita, Takashi Kinoshita, Tomoo Kishaba, Hideo Kita, Arihiro Kiyosue, Shigeru Komatsu, Kazuki Konishi, Sekiya Koyama, Makoto Kudo, Kazuhiko Machida, Hironi Makita, Hiroto Matsuse, Naoki Miyazawa, Hiroyuki Nakamura, Yuji Nakatani, Kazuyuki Nishimura, Takashi Nishimura, Junichi Ogawa, Hiroyuki Ohbayashi, Tetsuro Ohdaira, Tsukasa Ohnishi, Kazuhiko Oki, Masahiko Saito, Kenji Sakamoto, Osamu Sakamoto, Hisakuni Sekino, Noriharu Shijubo, Masaharu Shinkai, Hideo Soto, Yoshitaka Sugawara, Noriaki Suko, Hisaho Takahashi, Masamitsu Takahashi, Tsuneyuki Takahashi, Hiroshi Tanaka, Hiroyuki Taniguchi, Tadayuki Terada, Takao Tochigi, Kazuyo Tohyama, Hirokazu Tokuyasu, Keisuke Tomii, Tomomasa Tsuboi, Mitsuyoshi Utsugi, Katsumaru Yamamoto, Michiko Yamamoto, Shuichi Yano, Makoto Yoshida, Frank Custers, Richard Dekhuijzen, Remco Djamin, Jan Willem Van Dan Berg, Lowie Vanfleteren, Pascal Wielders, Bogusława Cimoszko, Anna Doboszyńska, Andrzej Dyczek, Andrzej Fal, Krystyna Folcik, Łukasz Goliński, Marek Jutel, Andrzej Kolczyński, Piotr Kuna, Ewa Łączyńska, Wojciech Machowiak, Maciej Marczak, Joanna Markiewicz, Janusz Milanowski, Grzegorz Mincewicz, Maria Nittner-Marszalska, Wojciech Papiewski, Małgorzata Pawlukiewicz, Witold Pomiećko, Barbara Rewerska, Cezary Rybacki, Wojciech Skucha, Ewa Trębas-Pietraś, Ewa Uhryn, Małgorzata Żurowska-Gębala, Laurentia Andrei, Traian Mihaescu, Stefan Mihaicuta, Eniko Vera Pall, Ioan Petrui, Angelica Savu, Claudia Toma, Ana Trailescu, Vladimir Abrosimov, Nataliya Astafyeva, Evgenyi Bazdyrev, Nadezhda Berdnikova, Laura Bolieva, Ekaterina Bukreeva, Valery Chistyakov, Anna Galustyan, Halida Gantseva, Svetlana Goncharova, Sergey Grigoriev, Galina Ignatova, Inna Ilyashevich, Nadezhda Izmozherova, Magomed Kamalov, Yaroslava Khovaeva, Natalia Kuzubova, Lyudmila Kvitkova, Liudmila Lenskaya, Igor Leshchenko, Olga Magnitskaya, Boris Molotilov, Artem Molotkov, Svetlana Myasoedova, Sergey Nedogoda, Vladimir Nosov, Marina Osipenko, Andrey Peskov, Veronika Popova, Oksana Ratushnay, Irina Ryzhova, Olga Shangina, Natalia Shaporova, Evgeny Shmelev, Lybov Shpagina, Alexander Shutkin, Yuri Shvarts, Mikhail Smirnov, Irina Stitsenko, Maksim Vasilev, Arkadiy Vertkin, Elena Vishneva, Alexander Vizel, Anna Zateyschikova, Mohamed Abdool-Gaffar, Ismail Abdullah, Axel Bruning, Nyda Fourie, Michael Greenblatt, Mohammed Tayob, K Venter, An Soo Jang, Kwan Ho Lee, Sang Haak Lee, Sook Young Lee, Suk Joong Yong, Kwang Ha Yoo, Soo Taek Uh, Ramón Agüero Balbín, David Ramos Barbón, Álvar Agustí García-Navarro, José Luis Velasco Garrido, Sergi Pascual Guardia, Eduard Monso Molas, Luis De Teresa Parreño, Borja García-Cosio Piqueras, German Peces-Barba Romero, Myriam Calle Rubio, Fernando Sánchez-Toril López, Alicia Marín Tapia, Heidi Martin Braschler, Martin Brutsche, Michael Grob, Jörg Leuppi, Daiana Stolz, Alexander Turk, Nawar Bakerley, Mona Bafadhel, Christopher Brightling, Rekha Chaudhuri, Gourab Choudhury, Graham Devereux, Imran Hussain, Kai Lee, William MacNee, Ravindran Mahadeva, Matthew Masoli, Monica Nordstrom, Manish Patel, Allan Reid, Dinesh Saralaya, Tariq Sethi, Sukh Dave Singh, Anthony G de Soyza, Tom Wilkinson, Alice Turner, Helen Ward, Chandar Abboy, Ivan Ackerman, Idalia Acosta, Arun Adlakha, Bassil Aish, Mohamed Ali, Charles Andrews, Robby Ayoub, Anil Badhwar, Dennis Bassetti, Sherif El Bayadi, Richard Beasley, Shashi Bellam, Jonathan Bernstein, Maria Blahey, Scott Bloom, Eugene Bleecker, Wesley Bray, Johnathan Brewer, Robert Buynak, William Calhoun, Edward Campbell, Anthony Captain, Birjis Chinoy, Kenneth Chinsky, Geoffrey Chupp, Arsenio Columbie, Clinton Corder, Gerard Criner, Humberto Cruz, Edward Cullen, Kevin Deboer, Michael Denenberg, Mark Dransfield, Leonard Dunn, Miles Elmore, David Erb, Faisal Fakih, Gary Ferguson, Charles Fogarty, Mark Freed, Stephen Fritz, David Fuentes, Shariar Cohen-Gadol, Robert Garver, John Given, Luis Ramos Gonez, Raul Ebran Gonzalez, Robert Gordon, Gregory Gottschlich, Donald Graham, David Grant, Gary Greenwald, James Greenwald, Kenneth Haft, Gregory Hammond, Nadia Hansel, Jeffrey Harris, Humberto Hernandez, Marvin Heuer, Albrecht Heyder, David Hill, Willis Holloway, Octavian Ioachimescu, Richard Jackson, Ajay Jain, Nan Jiang, Thomas Kaelin, Adolfo Kaplan, Mitchell Kaye, Akram Khan, Yekaterina Khronusova, Ryan Klein, Joel Kline, Firas Koura, Ritsu Kuno, Ware Kuschner, Jean Claude Labissiere, David Laman Jr, John Lee, Mitchell Lee, Lawrence Levinson, Njira Lugogo, M Mador, Nathaniel Marchetti, Rafael Martinez, Richard Martinez, Peter Mattar, David Maybee, Dennis McGraw, Michael McGuire, Curtis Mello, Aaron Milstone, John Mitchell, Wendy Moore, Timothy Moriarty, Cheta Nand, Brooke Nevins, Ikeadi Ndukwu, Rachel Nisbet, David Nyanjom, Maria Nualart, Thomas O'Brien, Mikhail Palatnik, Gnyandev Patel, Amit Patel, Guido Perez, Christopher Perry, Michael Pfeffer, Krishna Pudi, Marina Raikhel, Murali Ramaswamy, Joe Ramsdell, Donato Ricci, Gary Richmond, Eugene Ryan, Fadi Saba, Boris Sagalovich, C Andrew Schroeder, Timothy Scialla, Frank Sciurba, Amit Shah, Nirav Shah, Zeeshan Shaikh, Akhtar Siddiqui, Barry Sigal, Thomas Siler, Howard Silverboard, William Sims, Clyde Southwell, Selwyn Spangenthal, Peruvemba Sriram, James Stocks, Tony Su, John Suen, Robert Sussman, Horia Tatu, Antonio Terrelonge, Alan Thomas, Mario Torres, Rodolfo Trejo, Miguel Trevino, Banks Turner, Manuel Villareal, Janine Vintch, Neal Warshoff, Jan Westerman, Philip Wexler, Thomas Yunger, Amir Zeki, Mariano Fernandez Acquier, Norma Aramayo, German Arce, Juan Belloni, Víctor Cambursano, Carlos De La Vega, Fernando Rodriguez Chariarse, Pedro Elias, Marcelo Fernández, Ana Lopez, Andrea Medina, María Otaola, Maria Salazan Saez, Maria De Salvo, Fernando Scherbovsky, Ana Stok, Jorge Taborda, Alberto Tolcachier, Fernando Verra, Carlos Victorio, Rita Gisela Delgado Vizcarra, Philip Bardin, Peter Bremner, Martin Phillips, John Upham, Peter Wark, Antoine Bolly, Alain Delobbe, Peter Driesen, Eduard Janssens, Wim Janssens, Olivier Michel, Bernard Vandooren, Martti Antila, Jussara Fiterman, Carlos Fritscher, Jorge Hetzel, Jose Jardim, Waldo De Mattos, Rafael Martins, Maria Eunice De Oliveira, Andreia Pez, Maria Sales, Rafael Stelmach, Priscila Wolff, Svetla Andreeva, Reneta Antonova, Ana Dancheva, Yuliya Ivanova, Slavcho Ivanov, Hristo Metev, Iveta Naydenova, Tatyana Petkova, Galina Petrova, Kostadinka Sotirova, Mariyana Stoyanova, Rumen Tiholov, Iliyana Valkanova, Oleg Yakov, Rosa Feijoo, Juana Pavie, Patricia Schönffeldt, Absalon Silva, Victor Martinez, David Espinosa, Alejandro Londono, Dora Molina, Gonzalo Prada, Andrés Rico, Gregorio Sanchez Vallejo, Alvaro Urbina, Ana Vanegas, Maria Villegas, Josip Aralica, Gordana Stjepanovic, Vibeke Backer, Uffe Bødtger, Christian Meyer, Læge Sven Nielsen, Anders Loekke Ottesen, Ingrid Titlestad, Nathalie Bautin, Arnaud Bourdin, Pascal Chanez, Francis Couturaud, Antoine Cuvelier, Gilles Devouassoux, Pierre-Olivier Girodet, Jean-François Muir, Jean-Louis Pépin, Alain Proust, Azzedine Yaici, Yochai Adir, Gershon Fink, Zvi Fridlender, Gabriel Izbicki, Mordechai Kramer, Yehuda Schwartz, Juan Moreno Hoyos Abril, Ricardo Campos Cerda, Efraín Montaño Gonzalez, Ricardo Ramirez Terrones, Rodolfo Posadas Valay, Alejandra Ramirez-Venegas, Paul Dawkins, Syed Hussain, Benedict Brockway, John Richmond, Colin Helm, Catherina Chang, Jørn Ahlqvist, Terje Tollåli, Tadeusz Tomala, Socorro Castro, William Chavez, Octavio Cubas, Rolando Estrella, Efrain Felix, Ronal Gamarra, Alfredo Guerreros, Alberto Matsuno, Danilo Salazar, Miguel Tsukayama, Albert Albay Jr, Teresita Aquino, Tito Atienza, Joven Roque Gonong, Ronnie Samoro, Joel Santiaguel, Beata Asankowicz-Bargiel, Ewa Pisarczyk-Bogacka, Renata Bijata-Bronisz, Marta Chełmińska, Małgorzata Dobryniewska, Anna Olech-Cudzik, Tomasz Fijołek, Krzysztof Filipek, Agata Kot, Bożena Kucińska, Krzysztof Lis, Elżbieta Rybicka-Liszewska, Marzenna Tarnowska-Matusiak, Robert Mróz, Piotr Napora, Wojciech Naumnik, Artur Niemiec, Władysław Pierzchała, Grzegorz Przybylski, Katarzyna Styka, Danuta Wrońska, Branislava Milenkovic, Dobrivoje Novkovic, Matijaz Flezar, Niksa Segota, Snezana Ulcar Kostic, Albert Klobucar, Leif Bjermer, Dan Curiac, Christer Janson, Pekka Koskinen, Bo Lundback, Åke Olsson, Shih-Lung Cheng, Ming-Lin Ho, Jeng-Yuan Hsu, Wu-Huei Hsu, Ping-Hung Kuo, Chin-Chou Wang, Yu-Feng Wei, Kuang-Yao Yang, Watchara Boonsawat, Somchai Chantarothorn, Warangkana Keeratichananont, Kittipong Maneechotesuwan, Kanok Pipatvech, Piamlarp Sangsayunh, Sibel Arinc, Sermin Borekci, Arzu Kaner Erturk, Filiz Kosar, Hakan Gunen, Ismail Hanta, Pinar Akin Kabalak, Tunc Alp Demir, Sibel Nayci, Serir Aktogu Ozkan, Abdullah Sayiner, Esra Uzaslan, Viktor Blazhko, Volodymyr Gavrysyuk, Olena Golub, Liudmyla Iashyna, Tetiana Ilashchuk, Volodymyr Koshlia, Olena Krakhmalova, Vitali Kryvenko, Lesia Kuryk, Olena Levchenko, Yuriy Mostovoy, Mykola Ostrovskyy, Tetyana Pertseva, Olena Piura, Nadiya Rudnytska, Ganna Stupnytska, Nataliia Velychko, Oleh Yakovenko, Lilia Rodriguez Ables, Roger Abrahams, Bassil Aish, Jose Alvarez, Fernando Arencibia, Chander Arora, Samir Arora, Francis Averill, Kwabena Ayesu, Stephen Basheda, Steven Bauer, Jose Bautista, Matthew Beacom, Richard Beasley, Hernando Bernal, Subodh Bhuchar, J'Cinda Bitters, John Burk, Elizabeth Burkett, James Cain, Robert Call, Christopher Chappel, Bartolome Celli, Tom Christensen, Jeremy Cole, Jerome Daniel, Nguyen Dang, Enrique Davis, Samuel Deleon, Robert DeLuca, Ernesto Diaz, Anthony DiMarco, Calvin Dixon, Ankur Doshi, Hugh Durrence, Alain Eid, John Elsen, Herbon Fleming, May Flores, Charles Fogarty, Scott Franczek, Stephen Fritz, Gregory Funk, Stuart Garay, Bernard Garcia, Luis Ramos Gonez, Gregory Gottschlich, Joseph Graif, Carl Griffin, Yamirka Duardo Guerra, David Headley, Mitzie Hewitt, Susan Hole, Robert Holladay, Ira Horowitz, Yu-Luen Hsu, Jonathan Ilowite, Stephen Jones, Ravindra Kashyap, Edward Kerwin, Ahtaram Khan, Nicole Kimzey, James Krainson, Flory Kreutter, Kannappan Krishnaswamy, Shahrukh Kureishy, Albert Lai, Alex Lechin, Daria Lee, Marcus Lee, Williams Leeds, Joseph Lillo, Edward Lisberg, Lawrence Madoff, Narendra Maheskwari, Mujibur Majumder, Sashi Makam, Douglas Mapel, Matthew Mardiney, Jennifer Martin, David Maybee, Isaac Melamed, Elvin Mendez, Stuart Millstone, Joseph Montes, Lee Morrow, Frank Murphy, Dany Obeid, France Occy, Godson Oguchi, Juan Ortiz, Francisco Padron, Ward Paine, James Pearle, Enrique Pelayo, Vandely Perez, David Pham, Carlos Piniella, Kevin Pritchett, Padmashri Rastogi, Stephen Ryan, Syed Rehman, Jackson Rhudy, Eustace Riley, James Riser, Clifford Risk, Emory Robinette, Christopher Roney, Gary Ruoff, David Russian, Mercedes Samson, Jay Sandberg, Jose Santiago, William Sargeant, Alan Schecter, Frank Sciurba, Jeffrey Scott, Ilia Segal, Sudhir Sehgal, Frederic Seifer, Sudhir Sekhsaria, Richard Sellman, Paul Shapero, Jeffrey Shea, Lawrence Sher, John Sibille, Jawed Siddiqui, William Sims, Toniya Singh, Deren Sinkowitz, Denise Smyth, Daniel Soteres, Daniel Sousa, Ralph Steele, Thomas Stern, Jose Suarez, Sever Surdulescu, Ricardo Tan, Tonny Tanus, Raymond Tidman, Aurelio Torres-Consuegra, Barry Troyan, John Updegrove, Sanjay Vadgama, Armando Pineda-Velez, Eduardo Viera, Andrew Wachtel, Ralph Wade, Jimin Wang, Dave Webster, Paul Weinberg, Terry Wells, Jeffrey White, Bram Wieskopf, Hugh Windom, Patrick Wright, David Wyatt, Bassam Yousef, Zahid Zafar, Chau Ngo, Huong Le, Lan Nguyen, Thanh Nguyen, Nhung Nguyen
Subjects: Male, [SDV]Life Sciences [q-bio], 030204 cardiovascular system & hematology, Anti-asthmatic Agent, law.invention, Pulmonary Disease, Chronic Obstructive, Leukocyte Count, chemistry.chemical_compound, 0302 clinical medicine, Randomized controlled trial, law, Monoclonal, Receptors, Medicine, Anti-Asthmatic Agents, 030212 general & internal medicine, Humanized, COPD Exacerbations, benralizumab, clinical trials, COPD, Subcutaneous, General Medicine, Middle Aged, anti–IL-5Rα, Benralizumab, Pulmonary Disease, Chronic Obstructive/drug therapy, [SDV] Life Sciences [q-bio], Female, Antibodies, Monoclonal, Humanized/administration & dosage, Chronic Obstructive, Benralizumab COPD exacerbations, Injections, Subcutaneous, Socio-culturale, Aged, Antibodies, Monoclonal, Humanized, Double-Blind Method, Eosinophils, Humans, Patient Acuity, Receptors, Interleukin-5, Antibodies, chronic obstructive pulmonary disease, Injections, Pulmonary Disease, 03 medical and health sciences, Phase III, Anti-Asthmatic Agents/administration & dosage, In patient, business.industry, Eosinophils/metabolism, medicine.disease, Clinical trial, Receptors, Interleukin-5/antagonists & inhibitors, chemistry, Multicenter study, randomized controlled trial, Immunology, Interleukin-5, business
Abstract: BACKGROUND: The efficacy and safety of benralizumab, an interleukin-5 receptor alpha-directed cytolytic monoclonal antibody, for the prevention of exacerbations in patients with moderate to very severe chronic obstructive pulmonary disease (COPD) are not known.METHODS: In the GALATHEA and TERRANOVA trials, we enrolled patients with COPD (at a ratio of approximately 2:1 on the basis of eosinophil count [≥220 per cubic millimeter vs. RESULTS: In GALATHEA, the estimates of the annualized exacerbation rate were 1.19 per year (95% confidence interval [CI], 1.04 to 1.36) in the 30-mg benralizumab group, 1.03 per year (95% CI, 0.90 to 1.19) in the 100-mg benralizumab group, and 1.24 per year (95% CI, 1.08 to 1.42) in the placebo group; the rate ratio as compared with placebo was 0.96 for 30 mg of benralizumab (P = 0.65) and 0.83 for 100 mg of benralizumab (P = 0.05). In TERRANOVA, the estimates of the annualized exacerbation rate for 10 mg, 30 mg, and 100 mg of benralizumab and for placebo were 0.99 per year (95% CI, 0.87 to 1.13), 1.21 per year (95% CI, 1.08 to 1.37), 1.09 per year (95% CI, 0.96 to 1.23), and 1.17 per year (95% CI, 1.04 to 1.32), respectively; the corresponding rate ratios were 0.85 (P = 0.06), 1.04 (P = 0.66), and 0.93 (P = 0.40). At 56 weeks, none of the annualized COPD exacerbation rate ratios for any dose of benralizumab as compared with placebo reached significance in either trial. Types and frequencies of adverse events were similar with benralizumab and placebo.CONCLUSIONS: Add-on benralizumab was not associated with a lower annualized rate of COPD exacerbations than placebo among patients with moderate to very severe COPD, a history of frequent moderate or severe exacerbations, and blood eosinophil counts of 220 per cubic millimeter or greater (Funded by AstraZeneca [GALATHEA and TERRANOVA] and Kyowa Hakko Kirin [GALATHEA]; GALATHEA and TERRANOVA ClinicalTrials.gov numbers, NCT02138916 and NCT02155660.).
Published: 2019
Full Text: View/download PDF

14. COVID-19 patients’ sera induce epithelial mesenchymal transition in cancer cells

Author: Süheyla Kömür, Sedat Kuleci, Ismail Hanta, Hikmet Akkiz, Yasemin Saygideger, Aycan Sezan, Aslihan Candevir, Ezgi Ozyilmaz, Yeşim Taşova, Ezgi Derinoz, Efraim Güzel, Ferit Kuşcu, Burcu Saygıdeğer Demir, and Oya Baydar
Subjects: Adult, Cytotoxicity, Immunologic, Male, 0301 basic medicine, Cancer Research, medicine.medical_specialty, Epithelial-Mesenchymal Transition, Lung Neoplasms, Inflammation, Gastroenterology, Article, Metastasis, 03 medical and health sciences, 0302 clinical medicine, Cell Movement, Cell Line, Tumor, Neoplasms, Internal medicine, medicine, Humans, Epithelial–mesenchymal transition, RC254-282, Aged, Cell Proliferation, Cancer, SARS-CoV-2, business.industry, Immune Sera, EMT, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, COVID-19, Middle Aged, medicine.disease, Pathophysiology, Pneumonia, 030104 developmental biology, Oncology, 030220 oncology & carcinogenesis, Cancer cell, Female, ZEB1, SNAIL2, medicine.symptom, business, Fetal bovine serum
Abstract: Covid-19 Pneumonia of SARS-CoV-2 pandemic infection, persists to have high disease burden especially in cancer patients. Increased inflammation and thromboembolic processes are blamed to influence cancer patients more than the others but due to lack of knowledge regarding the pathophysiology of the both the virus itself and the response of the host, more basic and translational disease modeling research is needed to understand Cancer-Covid-19 interaction. In this study, serum samples from the patients, who were hospitalized due to Covid-19 pneumonia, applied to different cancer cells and cytotoxicity, motility, proliferation and gene expression analysis were performed. Serum samples derived from healthy volunteers and the fetal bovine serum that is used regularly in cell culture experiments used as controls. Hospitalized Covid-19 patients who had also cancer, were retrospectively screened, and their clinical course were recorded. Overall 12 Patient (PS) and 4 healthy serums (CS) were included in the experiments. PS applied cells showed increased motility in A549 cells as well as lost cell to cell connection in MCF7 and HCT116 cells, and induced expression of VIM, ZEB1 and SNAIL2 mRNA levels. Eight cancer diagnosed patients who were hospitalized due to Covid-19 between April and September 2020 were also reviewed retrospectively, which 5 of them were dead during SARS-CoV-2 infection. Thorax CT images of the 2 patients showed increased metastatic nodules in the lungs as of January 2021. The results of the study indicate that metastasis may be one of the prolonged consequences of COVID-19 pandemic in cancer sufferers.
Published: 2021
Full Text: View/download PDF

15. Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial

Author: William W Busse, Eugene R Bleecker, J Mark FitzGerald, Gary T Ferguson, Peter Barker, Stephanie Sproule, Richard F Olsson, Ubaldo J Martin, Mitchell Goldman, Anahí Yañez, Marcelo Fernández, Alberto Tolcachier, Juan Belloni, Jorge Taborda, Maria De Salvo, Jorge Maspero, Carlos Victorio, Miguel Chirino Navarta, Monica Grilli, Pablo Rodríguez, María Otaola, Víctor Cambursano, Patricia Malamud, Ana Stok, German Arce, Osiris Roza, Fernando Scherbovsky, Pedro Elias, Maria Salazan Saez, Matthew Peters, Martin Phillips, John Upham, Peter Gibson, Francis Thien, Jo Douglass, Paul Thomas, Philip Bardin, Dimitar Sajkov, Mark Hew, David Langton, Andreia Pez, Carlos Fritscher, Jorge Hetzel, Waldo Mattos, Rafael Stelmach, Martti Antila, Ana Luisa Fernandes, Hristo Metev, Yavor Ivanov, Aneliya Bogdanova, Ana Dancheva Markova, Marinka Peneva, Rumyana Veselinova, Tatyana Petkova, Vanushka Petrova, Elena Shopova, Yuliya Ivanova, Rumyana Yotsova, Ginka Kirkova, Galina Petrova, Svetoslav Dachev, Kostadinka Sotirova, Mariyana Stoyanova, Oleg Yakov, Vanya Ilieva-Fartunova, Catherine Lemiere, Michel Laviolette, William Yang, Bonavuth Pek, William Patrick Killorn, Claude Poirier, Guy Chouinard, Lyle Melenka, Richard Leigh, Parameswaran Nair, Delbert Dorscheid, James Martin, Juana Pavie, Andres Rosenblut, Claudia Cartagena, Carlos Quilodran, Silvia Muñoz, Ivana Malkusova, Josef Veverka, Stanislav Holub, Jaroslav Mares, Radovan Kozel, Daniela Kopecka, Vladimir Zindr, Pavel Cerva, Pascal Chanez, Arnaud Bourdin, Gilles Devouassoux, Camille Taille, Frédéric De Blay, Francois Goupil, Christophe Leroyer, Delphine Gourcerol, Toufik Didi, Alain Didier, Gilles Garcia, Philippe Bonniaud, Riazate Rossanaly Vasram, Marek Lommatzsch, Ulf Harnest, Anneliese Linnhoff, Claus Keller, Gerhard Hoheisel, Karin Förster, Thomas Schultz, Isabelle Schenkenberger, Joachim Kirschner, Tibor Schmoller, Stefan Zielen, Marc Kornmann, Ekkehard Beck, Lutz Volgmann, Rolf Dichmann, Axel Overlack, Jörg Winkler, Petra Mikloweit, Sabine Ballenberger, Mathias Rolke, Stephanie Korn, Helmut Pabel, Martin Hoffmann, Jan Feimer, Klaus Rabe, Regina Deckelmann, Tobias Welte, Hiroyuki Ohbayashi, Soichiro Hozawa, Terufumi Shimoda, Makoto Yoshida, Toshikazu Nagakura, Tadashi Kamei, Yasuyuki Sano, Shinichiro Kagami, Hisaho Takahashi, Michiko Haida, Goro Kimura, Hiroyuki Nakamura, Yasuo To, Masaharu Shinkai, Tadasuke Shimokawaji, Makoto Kudo, Noriharu Shijyubo, Takao Tochigi, Motokazu Kato, Akihiko Tanaka, Yasuhiro Gon, Norihisa Sasaki, Tetsuro Ohdaira, Chiharu Omori, Toshiki Takahashi, Satomi Takeuchi, Kiyotaka Nakajima, Hironi Makita, Masahiro Kaneko, Kenjiro Furuta, Masami Taniguchi, Yoshito Inobe, Hiroshi Miki, Yoichi Nakamura, Naoki Miyazawa, Shuichi Yano, Masayuki Iijima, Tsuyoshi Yamato, Javier Diaz, Alberto Matsuno, Efrain Felix, Alfredo Guerreros, Alejandro Daly, Fernando Rodriguez Chariarse, Danilo Salazar, Socorro Castro, William Chavez, Rolando Estrella, Teresita Aquino, Tito Atienza, Ronnie Samoro, Marie Grace Dawn Isidro, Piotr Kuna, Adam Antczak, Michał Bednarek, Danuta Mądra-Rogacka, Teresa Hofman, Marek Jutel, Ewa Pisarczyk-Bogacka, Agata Kot, Robert Mróz, Małgorzata Czupryńska-Borkowska, Małgorzata Żurowska-Gębala, Andrzej Dyczek, Grażyna Jasieniak-Pinis, Piotr Wojnowski, Ewa Trębas-Pietraś, Małgorzata Dobryniewska, Marcin Stobiecki, Marzenna Tarnowska-Matusiak, Alina Magner, Andrzej Kolczyński, Tomasz Kachel, Zbigniew Bartuzi, Bernadetta Majorek-Olechowska, Paweł Śliwiński, Violetta Balicka, Elżbieta Hajoł, Jacek Stachera, Marta Rachel, Marek Michnar, Jarosław Tałałaj, Ewa Springer, Piotr Napora, Tomasz Grzelewski, Renata Bijata-Bronisz, Anna Świderska, Grzegorz Mincewicz, Zbigniew Sankowski, Tomasz Fijołek, Artur Kwaśniewski, Joanna Jerzyńska, Jerzy Cygler, Ryszard Olesiejuk, Iwona Von Steiner, Wojciech Machowiak, Krzysztof Filipek, Piotr Piskorz, Ewa Uhryn, Marita Nittner-Marszalska, Elżbieta Rybicka-Liszewska, Anna Bodzenta-Łukaszyk, Marta Chełmińska, Izabella Krupa-Borek, Wojciech Skucha, Anna Płoszczuk, Traian Mihaescu, Ioan Dorin Petrui, Angelica Savu, Ghiulten Apti, Claudia Toma, Ana Trailescu, Sergei Sokurenko, Vasiliy Trofimov, Igor Leshchenko, Natalia Shaporova, Inna Ilyashevich, Irina Stitsenko, Alexander Vizel, Yulia Ilkovich, Dmitrii Tikhanov, Svetlana Goncharova, Andrey Ezhov, Galina Ignatova, Nadezhda Izmozherova, Nadezhda Berdnikova, Ludmila Goryachkina, Veronika Popova, Laura Bolieva, Andrey Rebrov, Vladimir Nosov, Olga Magnitskaya, Sergey Nedogoda, Vladimir Abrosimov, Artem Molotkov, Galina Reshedko, Mikhail Smirnov, Marina Osipenko, Elena Pavlysh, Svetlana Myasoedova, Liudmila Lenskaya, Valery Chistyakov, Elena Vishneva, Liliya Uon, Anna Zateyschikova, Svetlana Laleko, Tatiana Pak, Axel Bruning, Visvakuren Naidoo, Jeevren Reddy, Richard Van Zyl Smit, Hae-Sim Park, Young Joo Cho, Sang-Heon Cho, Sang Haak Lee, Byung Jae Lee, Ju Sang Kim, You Sook Cho, Choon-Sik Park, Mi-Kyeong Kim, Young-Il Koh, Joo-Hee Kim, Sook Young Lee, Sang Pyo Lee, Jung Won Park, Kwang Ha Yoo, Hyoungkyu Yoon, Jaechun Lee, Gyu-Young Hur, Soo Keol Lee, HeeKyoo Kim, David Ramos Barbón, Elena Laffond Yges, Eva Martínez Moragón, Miguel Arias Guillen, Alberto Saura Vinuesa, Fernando Sánchez-Toril López, José Luis Velasco Garrido, Borja García-Cosio Piqueras, Luis Pérez de Llano, Antonio Luis Valero Santiago, Myriam Calle Rubio, Leif Bjermer, Bo Lundbäck, Bilun Gemicioglu, Sevim Bavbek, Dane Ediger, Munevver Erdinc, Ismail Hanta, Sibel Nayci, Sibel Arinc, Liudmyla Iashyna, Yuriy Mostovoy, Mykola Ostrovskyy, Lesia Kuryk, Ivan Lemko, Tetyana Ospanova, Liubov Moskalenko, Oleksii Korzh, Viktor Blazhko, Olena Krakhmalova, Liliia Romaniuk, Yevgeniya Dytyatkovs'ka, Oleh Yakovenko, Volodymyr Gavrysyuk, Hassan Burhan, Dinesh Saralaya, Stephen Scott, Alyn Morice, Ewart Jackson-Voyzey, Thida Win, Shuab Nasser, Richard Harrison, Rekha Chaudhuri, Monica Nordstrom, Pradip De, Matthew Masoli, Adel Mansur, Anthony Gunstone, Robert Niven, Timothy Harrison, Suresh Babu, Subodh Bhuchar, Shahrukh Kureishy, John Zwetchkenbaum, Lawrence Kaplan, Eugene Bleecker, Santiago Reyes, Faisal Fakih, Marvin Heuer, Ryan Klein, Michael Marcus, Iftikhar Hussain, Tonny Tanus, Hengameh Raissy, Sady Alpizar, Hector Rodriguez, Gerald Gleich, Tracy Bridges, Joe Pouzar, Gary Steven, Jonathan Matz, Shana Krstevska, Dama Ziworitin, Adolfo Kaplan, James Sublett, James DeAngelo, Amy Darter, John Agaiby, John Hagan, Enrique Davis, Dareen Siri, Charlene Mcevoy, Chrisette Dharma, Najmuddin Karimjee, Steven Kelsen, Manuel Frade, Amy Silverthorn, Joel Kline, Francis Averill, Jose Ruiz, Emory Robinette, Zeeshan Shaikh, Carlos Aguilar, William Nish, German Alvarez, Younus Ismail, Purvi Parikh, Mila Leong, Dennis Murphy, Francisco Garcia, Alan Goldsobel, Antonio Blanco, Edward Campbell, Guido Perez, Geoffrey Chupp, Toby Bates, Vandely Perez, Sally Wenzel, Kartik Shenoy, Rohit Katial, David Bernstein, Neil Parikh, William Sims, Gary Ferguson, David Pham, Anu George, Richard Beasley, Gilberto Perez, Robert Garver, Miriam Garcia-Portela, Stephen Wong, Weily Soong, Richard Guillot, Golda Hudes, Ahmed Arif, Josefa Binker, Manuel Villareal, Ulrike Ziegner, Joseph Ojile, Sanjeev Goswami, Carlos Piniella, Ilia Segal, Heidi Zafra, Mitchell Lee, Martha Tarpay, John Panuto, Rajan Merchant, Peter Springsteen, Timothy Scialla, Paul Shapero, Karen Allen, Mark Moss, Humberto Cruz, Jeffrey Rumbyrt, Amy Boyd, Robert Nathan, Jonathan Bernstein, Joshua Jacobs, Elliot Ginchansky, Janice Johnston, Barbara Baxter, Thomas Johnson II, Stephen Apaliski, Clinton Corder, David Fuentes, Joseph Diaz, Chau Ngo, Lan Le, Department of Medicine, University of Wisconsin-Madison-School of Medicine and Public Health, Fundación Cidea Allergy and Respiratory Research Unit, University of Oxford [Oxford], University of Newcastle, Newcastle, NSW Australia., Defence Science and Technology Laboratory (Dstl), Ministry of Defence (UK) (MOD), Organização Multinacional de Formação, Agence Universitaire de la Francophonie (AUF), University of Calgary, Centre recherche en CardioVasculaire et Nutrition = Center for CardioVascular and Nutrition research (C2VN), Institut National de la Recherche Agronomique (INRA)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Physiologie & médecine expérimentale du Cœur et des Muscles [U 1046] (PhyMedExp), Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), laboratoire du sommeil, CHU Grenoble, Physiopathologie et Epidémiologie des Maladies Respiratoires (PHERE (UMR_S_1152 / U1152)), Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Strasbourg, Centre Hospitalier du Mans, Groupe d'Etude de la Thrombose de Bretagne Occidentale (GETBO), Université de Brest (UBO)-Institut Brestois Santé Agro Matière (IBSAM), Université de Brest (UBO)-Université de Brest (UBO), CIC Brest, Université de Brest (UBO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hôpital de la Cavale Blanche, Service de pneumologie, Centre hospitalier de la région d'Annecy, Cytokines, chimiokines et immunopathologie, Université Paris-Sud - Paris 11 (UP11)-IFR13-Institut National de la Santé et de la Recherche Médicale (INSERM), J.W. Goethe Universität, Institut für Geowissenschaften, Altenhöferallee 1, D-60438 Frankfurt am Main, Germany, Department of Pulmonary Medicine, Leiden University Medical Center (LUMC), Hannover Medical School [Hannover] (MHH), Japan Energy Corporation, Medical University of Łódź (MUL), Wroclaw Medical University, Saint-Petersburg State University, Physical Department, Petrodvoretz, 194508 St.-Petersburg, Russia, Physical Department (PD), St Petersburg State University (SPbU)-St Petersburg State University (SPbU), Ankara University, Oak Ridge National Laboratory [Oak Ridge] (ORNL), UT-Battelle, LLC, Department of Earth Sciences, University of Cambridge, University of Cambridge [UK] (CAM), Center for Genomics and Personalized Medicine, Wake Forest University, Mayo Clinic [Rochester], Department of Wildlife Management, Pir Mehr Ali Shah Arid Agriculture University, Lab Biotecnol Bacteriana, Inst Ciencia & Tecnol Alimentos & Nutr ICTAN, Universidade da Coruña, Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), Institut Brestois Santé Agro Matière (IBSAM), Université de Brest (UBO)-Université de Brest (UBO)-Université de Brest (UBO), Centre recherche en CardioVasculaire et Nutrition (C2VN), Université de Brest (UBO), University of Oxford, University of Newcastle [Callaghan, Australia] (UoN), Université de Brest (UBO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Brestois Santé Agro Matière (IBSAM), Universiteit Leiden-Universiteit Leiden, Wrocław Medical University, Department of Earth Sciences [University of Cambridge], and Pir Mehr Ali Shah Arid Agriculture University = PMAS-Arid Agriculture University Rawalpindi (AAUR)
Subjects: Adult, Male, Pulmonary and Respiratory Medicine, medicine.medical_specialty, Adolescent, [SDV]Life Sciences [q-bio], Antibodies, Monoclonal, Humanized, Placebo, [SDV.MHEP.PSR]Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tract, Time, law.invention, Young Adult, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Double-Blind Method, Randomized controlled trial, law, Internal medicine, Clinical endpoint, Humans, Medicine, Anti-Asthmatic Agents, 030212 general & internal medicine, Child, Adverse effect, ComputingMilieux_MISCELLANEOUS, Aged, Asthma, business.industry, Middle Aged, medicine.disease, Benralizumab, 3. Good health, Clinical trial, Treatment Outcome, 030228 respiratory system, Tolerability, chemistry, Female, business, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology, Follow-Up Studies
Abstract: Benralizumab is an interleukin-5 receptor α-directed cytolytic monoclonal antibody that has been shown to safely reduce exacerbations and improve lung function for patients with asthma. We assessed the long-term safety and efficacy of benralizumab for patients with severe, uncontrolled eosinophilic asthma.We conducted a randomised, double-blind, parallel-group, phase 3 extension study at 447 sites in 24 countries. Eligible patients had to have completed the SIROCCO or CALIMA trials and remained on subcutaneous benralizumab 30 mg every 4 weeks (Q4W) or every 8 weeks (Q8W). Patients who had received placebo in those trials were re-randomised in a 1:1 ratio, using an interactive web-based system, to benralizumab 30 mg either Q4W or Q8W (first three doses 4 weeks apart). Treatment lasted for 56 weeks for adult patients (age ≥18 years) and 108 weeks for adolescent patients (age 12-17 years). The primary endpoint was the safety and tolerability of the two dosing regimens of benralizumab up to 68 weeks for adult patients (including the follow-up visit post-treatment) and up to 56 weeks for adolescent patients. This endpoint was assessed in the full analysis set, which included all patients from the SIROCCO and CALIMA predecessor studies who received at least one dose of study treatment in BORA and did not continue into another trial. This study is registered with ClinicalTrials.gov (NCT02258542).Between Nov 19, 2014, and July 6, 2016, we enrolled 1926 patients, of whom 633 had received benralizumab Q4W and 639 had received benralizumab Q8W in SIROCCO or CALIMA. The remaining 654 patients had received placebo in those trials and were randomly re-assigned in this trial to receive benralizumab Q4W (n=320) or Q8W (n=334). 1576 patients, including 783 who received benralizumab Q4W (265 newly assigned) and 793 who received benralizumab Q8W (281 newly assigned), were included in the full analysis set. The most common adverse events in all groups were viral upper respiratory tract infection (14-16%) and worsening asthma (7-10%). The most common serious adverse events were worsening asthma (3-4%), pneumonia (1% to 1%), and pneumonia caused by bacterial infection (0-1%). The percentages of patients who had any on-treatment adverse event, any serious adverse event, or any adverse event leading to treatment discontinuation during BORA were similar between patients originally assigned benralizumab and those originally assigned placebo and between benralizumab treatment regimens. The percentage of patients who had any adverse event was similar between SIROCCO or CALIMA (71-75%; benralizumab group only) and BORA (65-71%), as was the percentage of patients who had an adverse event that led to treatment discontinuation (2% in SIROCCO and CALIMA vs 2-3% in BORA).The 2 years of safety results validate that observations observed in the first year of benralizumab continued through a second year of treatment. No new consequences of long-term eosinophil depletion occurred, and the incidence of other adverse events, including opportunistic infections, were similar during the second year.AstraZeneca and Kyowa Hakko Kirin.
Published: 2019
Full Text: View/download PDF

16. The role of HLA-DRB1* alleles in prediction of long term prognosis in sarcoidosis

Author: Sedat Kuleci, Ismail Hanta, Eren Erken, Ali Kocabas, Ezgi Ozyilmaz, Ozlem Goruroglu Ozturk, Ali Durmaz, Orhan Othman Hasan, and Bugra Guzelbaba
Subjects: medicine.medical_specialty, business.industry, Human leukocyte antigen, medicine.disease, Extra pulmonary, Gastroenterology, Pulmonary function testing, Term (time), DLCO, Internal medicine, Medicine, Sarcoidosis, Allele, business, HLA-DRB1
Abstract: A wide range of HLA-DR alleles are reported to be associated with sarcoidosis either in term of disease progression or extra pulmonary involvement, however the effect on long term prognosis in different ethnic groups is not fully understood. The aim of this study was to investigate the relationship between HLA-DRB1 alleles and complete resolution status at 5 years in sarcoidosis. Methods: 91 patients who were histopathologically diagnosed in Cukurova University Faculty of Medicine Department of Chest Diseases between 1993- 2012 were included in the study. All patients underwent HLA analysis by the Sequence Specific Oligonucleotide Prob (SSOP) method. 27 patients were excluded from the study group due to lack of regular follow-up and not yet passed 5 years since diagnosis. Complete resolution at 5th year was defined according to the predefined standard criteria (ACCESS). Results: At 5th year after diagnosis, the complete resolution rate was 43 %. The HLA-DRB1*14 allele was significantly higher in patients without complete resolution (22 vs 0 %)(p=0.008). When patients with or without complete resolution compared; age, gender, smoking history, symptom duration and pulmonary function test results were similar however, in patients without complete resolution; extra-pulmonary involvement was more common (55% vs 21%)(p=0.010), treatment requirement ratio (61% vs. 21%)(p=0.002) and recurrence rate was higher(30% vs 7%)(p=0.030) and the initial carbonmonoxide diffusion test(DLCO) value was lower(71.3 +/- 18.4 vs. 82.5+/- 14.9)(p=0.010). Discussion: HLA-DRB1*14 alleles could predict long term resolution in sarcoidosis and early prediction of long term resolution could improve prognosis.
Published: 2017
Full Text: View/download PDF

17. Riociguat Use in a Patient with Sickle Cell Anemia Related Chronic Thromboembolic Pulmonary Hypertension

Author: Orhan Othman, Ismail Hanta, Oya Baydar, and Caglar Emre Caglayan
Subjects: medicine.medical_specialty, business.industry, Internal medicine, medicine, Cardiology, Chronic thromboembolic pulmonary hypertension, medicine.disease, business, Riociguat, Sickle cell anemia, medicine.drug
Published: 2019
Full Text: View/download PDF

18. TERT Mutation Analysis in IPF Patients: A Pilot Cohort Study

Author: Yusuf Gozet, Sule Menziletoglu Yildiz, Ismail Hanta, Oya Baydar Toprak, and Gozde Sarar Yilmaz
Subjects: Oncology, medicine.medical_specialty, business.industry, Internal medicine, medicine, Mutation testing, business, Cohort study
Published: 2019
Full Text: View/download PDF

19. A case of Non-Hodgkin lyphoma mimicking diffuse parenchymal lung disease

Author: Efraim Güzel, Ismail Hanta, Emine Kilicbagir, Oya Baydar, and Alper Avci
Subjects: Thorax, medicine.medical_specialty, Systemic disease, Lung, medicine.diagnostic_test, business.industry, Physical examination, medicine.disease, Pulmonary function testing, Surgery, medicine.anatomical_structure, Cardiothoracic surgery, medicine, Crackles, Radiology, medicine.symptom, business, Wedge resection (lung)
Abstract: 53 year-old male patient admitted to our clinics with progressive dyspnea for 2 years. He was a farmer with a 30 packagge*year cigarette history. Physical examination of the patient who has neither any systemic disease nor chronic drug use,revealed bilateral diffuse crackles and clubbing. He has restriction and diminished diffusion capacity on pulmonary function tests. Thorax computerized tomography showed bilateral subpleural ground-glass opasities, honey combing and fibrotic dansities. He has no prior history of rheumatological disease. As fiberoptic bronchoscopy cytologic and cultural examination was normal, diagnostic video associated thoracic surgery performed. Pathologic interpretation of wedge resection material was consistent with 9non-hodgkin lymphoma: extranodal marginal zone so nowadays he has underwent the clinical follow-up of mediacl oncology department. In this paper, a very rare, primary lung non-hodgkin lyphoma case presenting with radiological findings as seen in diffuse parenchymal lung disease is presented.
Published: 2016
Full Text: View/download PDF

20. Profile of Respiratory Impairment in Patients With Amyotrophic Lateral Sclerosis at Initial Admittance

Author: Filiz Koç, Ismail Hanta, Sedat Kuleci, and Çukurova Üniversitesi
Subjects: medicine.medical_specialty, Admittance, respiratory impairment, business.industry, Respiratory impairment, medicine.disease, pulmonary function tests, Internal medicine, medicine, Cardiology, Surgery, In patient, Neurology (clinical), ALS, Amyotrophic lateral sclerosis, business
Abstract: PURPOSE: To evaluate the initial respiratory impairments [pulmonary functions and arterial blood gases (ABGs)] in patients with amyotrophic lateral sclerosis (ALS) according to Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) at the time of admission. METHOD: Forty-five patients with ALS were evaluated between January 2004 and December 2007 by pulmonary function tests (PFTs) and ABG results at the time of admission. ALSFRS-R was used to quantify the severity of ALS patients. ALS patients were divided into 2 subgroups according to their ALSFRS-R scores as equal or below 26 (group 1, moderate-severe) and above 26 (group 2, mild). PFTs and ABG results were compared between these 2 subgroups. RESULTS: As 13 of the 45 patients with ALS were unable to perform PFTs, data of only 32 patients were evaluated (n=7 for group 1, n=25 for group 2). PFTs and ABG results except for forced expiratory volume in the first second (FEV1)/forced vital capacity (FVC) % (P=0.003) and partial arterial oxygen tension (pO2) (P=0.02) did not differ significantly between the 2 groups. While FEV1/FVC (r=-0.42, P=0.01) was negatively correlated with ALSFRS-R score, pO2 (r=0.36, P=0.02) was positively correlated. CONCLUSIONS: We thought that the increase in FEV1/FVC (%) was more susceptible for reflecting early respiratory impairments than FVC (%) in ALS patients at the initial admittance. Copyright © 2010 by Lippincott Williams & Wilkins.
Published: 2010
Full Text: View/download PDF

21. Gemcitabine, Vinorelbine, and Cisplatin in the Treatment of Advanced Nonsmall Cell Lung Cancer

Author: Meltem Karatasli, Serap Hastürk, Ismail Hanta, Nilgun Hatabay, Ferah Ece, and Çukurova Üniversitesi
Subjects: Adult, Male, Oncology, Cancer Research, medicine.medical_specialty, Lung Neoplasms, medicine.medical_treatment, Adenocarcinoma, Neutropenia, Vinblastine, Vinorelbine, Deoxycytidine, Carcinoma, Non-Small-Cell Lung, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, Humans, Medicine, Survival rate, Aged, Neoplasm Staging, Cisplatin, Chemotherapy, Performance status, Nonsmall cell lung cancer, business.industry, Middle Aged, Prognosis, medicine.disease, Gemcitabine, Survival Rate, Treatment Outcome, Carcinoma, Squamous Cell, Female, Triplet chemotherapy, Neoplasm Recurrence, Local, business, Febrile neutropenia, medicine.drug
Abstract: PubMedID: 19433960 Objectives: Currently, cisplatin-based doublet combinations are accepted to be the first-line chemotherapy for advanced nonsmall cell lung cancer (NSCLC). Although triplet chemotherapeutics have been shown to be more effective and active than doublets, their toxicity was higher as expected. Therefore, we conducted this phase II trial using the combination of gem-citabine-cisplatin- vinorelbine with lower than usual but acceptable doses of gemcitabine and cisplatin to obtain higher response rate than doublet but less toxicity than triplet combinations. Methods: In this trial, stage IIIB and IV chemotherapy naive NSCLC patients with measurable disease and performance status of 0 to 2 were included. Gemcitabine and vinorelbine at the doses of 900 mg/m 2 and 25 mg/m 2, respectively were administered on days 1 and 8, and cisplatin at a dose of 50 mg/m 2 on day 1, every 21 days. Results: Three of the 39 patients included in the trial were complete responders (7.7%). The overall response rate was 56.4%, median time to the progression was 6 months, median overall survival time was 12 months, and 1-year survival rate was 49.6%. Grade II to III neutropenia and thrombocytopenia occurred in 24% and 30% of the patients, respectively. Febrile neutropenia was observed in 13.5% of the patients and only these patients received G-CSF. Platelet and erythrocyte transfusions were required in 12 (32.4%) patients. No toxic or early death was observed. Conclusions: This combination of gemcitabine-cisplatin-vinorelbine with lower doses of cisplatin and gemcitabine was effective and active in advanced NSCLC. The overall response rate, 1-year survival and median survival time were nearly similar to previous trials in which higher doses of these 3 drugs were used. The toxicities were more acceptable and manageable than the regimes with higher doses; therefore, we may suggest a treatment option for advanced stage NSCLC. Copyright © 2009 by Lippincott Williams & Wilkins.
Published: 2009
Full Text: View/download PDF

22. Isolated Hepatic Tuberculosis Presenting as Cystic-Like and Tumour-Like Mass Lesions

Author: Ismail Hanta, Cem Kaan Parsak, Ömer Alabaz, and Ahmet Aslan
Subjects: Hepatic tuberculosis, medicine.medical_specialty, Pathology, Tuberculosis, business.industry, Gastroenterology, Solid mass, Cystic liver lesions, Histopathological examination, Published: January 2008, medicine.disease, Liver abscesses, Cystic lesion, medicine, lcsh:Diseases of the digestive system. Gastroenterology, Radiology, lcsh:RC799-869, business, Liver abscess
Abstract: Hepatic tuberculosis is a rare manifestation of extra-pulmonary tuberculosis. Hepatic tuberculous lesions are especially mimicking tumour-like mass or cystic lesions in the liver and so can be misdiagnosed with several diseases. Histopathological examination of the specimen is essential in the diagnosis for hepatic tuberculosis. In this report, two cases with hepatic tuberculosis having cystic solid mass and abscess liver lesions are described.
Published: 2008
Full Text: View/download PDF

23. Chlamydophila Pneumoniae Infection in Adult Asthmatics Patients

Author: Ismail Hanta, Sedat Kuleci, Murat Avsar, Fatih Köksal, Ali Kocabas, and Çukurova Üniversitesi
Subjects: Adult, Male, Pulmonary and Respiratory Medicine, medicine.medical_specialty, Pathogenesis, medicine.disease_cause, Polymerase Chain Reaction, Gastroenterology, C. pneumoniae, Internal medicine, Throat, Healthy control, Pneumonia, Bacterial, Prevalence, medicine, Humans, Immunology and Allergy, In patient, Prospective Studies, Chlamydophila Infections, Asthma, Asthma exacerbations, business.industry, Significant difference, Mean age, Chlamydophila pneumoniae, medicine.disease, medicine.anatomical_structure, Pediatrics, Perinatology and Child Health, Immunology, Female, business
Abstract: PubMedID: 18259994 Objectives: This study has attempted to investigate the prevalence of Chlamydophila pneumoniae (CP) infection in patients with asthma. Methods: A total of 84 patients with stable asthma (58 males + 26 females; mean age ± SD; 37.3 ± 11.0 years), 22 patients with asthma exacerbation (17 males + 5 females; mean age ± SD; 33.2 ± 9.1 years), and 34 healthy adults (18 males + 16 females; mean age ± SD; 30.4 ± 11.5 years) were included in the study. Serum and throat wash samples were obtained from all patients and healthy controls 2 times, 1 month apart. Micro Immuno Fluorescence method for detecting CP antibodies in serum, and polymerase chain reaction (PCR) method for detecting presence of CP infection in the throat wash samples were used. Results: The frequency of PCR positivity for CP in throat wash samples was higher in the patients with stable asthma (28.6%) than in healthy control group (11.8%) (p < 0.01). However no significant difference was found between healthy control group and asthma exacerbated group (22.7%) (p > 0.05). In addition, seroprevalences of acute and chronic CP infections were not different between patient and control groups (p > 0.05). Serological acute infection for CP was not detected among patients with positive PCR results. In contrast, although not statistically significant, serologically chronic infection for CP was detected in 3 (60%) of 5 patients with asthma exacerbation, in 18 (75%) of 24 patients with stable asthma, and 2 (50%) of 4 with healthy controls (p > 0.05). Conclusion: CP infection detected by the PCR method was more prevalent among patients with stable asthma and chronic/persistant CP infection might have an important role in asthma pathogenesis. Copyright © 2008 Informa Healthcare USA, Inc.
Published: 2008
Full Text: View/download PDF

24. Ultrasound accelerated thrombolysis may be an effective and safe treatment modality for intermediate risk/submassive pulmonary embolism

Author: Onur Sinan Deveci, Ali Deniz, Ismail Hanta, Ayca Acikalin Akpinar, Mesut Demir, Mehmet Kanadaşı, Caglar Ozmen, Aziz Inan Celik, Nezihat Rana Dişel, Ayhan Usal, Huseyin Tugsan Balli, Rabia Eker Akilli, Caglar Emre Cagliyan, Halil Aktas, Çukurova Üniversitesi, Tıp Fakültesi, Cerrahi Tıp Bilimleri Bölümü, Kalp ve Damar Cerrahisi Anabilim Dalı, Çukurova Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Acil Tıp Anabilim Dalı, Çukurova Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Radyoloji Anabilim Dalı, Çukurova Üniversitesi, Tıp Fakültesi, Cerrahi Tıp Bilimleri Bölümü, Göğüs Cerrahisi Anabilim Dalı, Özmen, Çağlar, Deniz, Ali, Eker Akıllı, Rabia, Deveci, Onur Sinan, Çağlıyan, Çağlar Emre, Aktaş, Halil, and Çelik, Aziz İnan
Subjects: Male, medicine.medical_specialty, Circulatory collapse, medicine.drug_class, Deep vein, medicine.medical_treatment, Ultrasonic Therapy, Ventricular Dysfunction, Right, 030204 cardiovascular system & hematology, 03 medical and health sciences, 0302 clinical medicine, Risk Factors, Internal medicine, Multidetector Computed Tomography, medicine, Natriuretic peptide, Humans, Thrombolytic Therapy, 030212 general & internal medicine, Right ventricular dysfunction, Infusions, Intravenous, Retrospective Studies, biology, business.industry, Mortality rate, General Medicine, Thrombolysis, Middle Aged, medicine.disease, Troponin, Thrombosis, Pulmonary embolism, medicine.anatomical_structure, Treatment Outcome, Tissue Plasminogen Activator, biology.protein, Cardiology, Ventricular Function, Right, Female, Hypotension, Cardiology and Cardiovascular Medicine, business, Pulmonary Embolism
Abstract: PubMedID: 26673444 Pulmonary embolism (PE) is a potentially life-threatening condition and the fact that 90% of PE originate from lower limb veins highlights the significance of early detection and treatment of deep vein thrombosis.1) Massive/high risk PE involving circulatory collapse or systemic arterial hypotension is associated with an early mortality rate of approximately 50%, in part from right ventricular (RV) failure.2) Intermediate risk/submassive PE, on the other hand, is defined as PE-related RV dysfunction, troponin and/or B-type natriuretic peptide elevation despite normal arterial pressure.3) Without prompt treatment, patients with intermediate risk PE may progress to the massive category with a potentially fatal outcome. In patients with PE and right ventricular dysfunction (RVD), in hospital mortality ranges from 5% to 17%, significantly higher than in patients without RVD.4,5). © 2016, International Heart Journal Association. All rights reserved.
Published: 2016

25. Isoniazid intervention for latent tuberculosis among 86 patients with rheumatologic disease administered with anti-TNFα

Author: Ismail Hanta, Süleyman Özbek, Murat Sert, Ali Kocabas, Sedat Kuleci, and Çukurova Üniversitesi
Subjects: Adult, Male, medicine.medical_specialty, Antitubercular Agents, Arthritis, Gastroenterology, Arthritis, Rheumatoid, Psoriatic arthritis, Rheumatology, Rheumatic Diseases, Internal medicine, Isoniazid, Humans, Tuberculosis, Medicine, Spondylitis, Ankylosing, Aspartate Aminotransferases, Prospective Studies, Prospective cohort study, Ankylosing spondylitis, Latent tuberculosis, Tumor Necrosis Factor-alpha, business.industry, Arthritis, Psoriatic, Alanine Transaminase, General Medicine, Middle Aged, bacterial infections and mycoses, medicine.disease, anti-TNF alpha therapy, Rheumatoid arthritis, Immunology, Isoniazid intervention, Colorimetry, Female, Anti-TNF? therapy, business, medicine.drug
Abstract: WOS: 000249813700012 PubMed ID: 17332973 In this study, we investigated the safety and toxicity of isoniazid (INH) intervention therapy to the patients with latent tuberculosis who were given tumor necrosis factor alpha (TNF alpha) for the treatment of their rheumatologic diseases. In this prospective clinical study, we enrolled 86 patients receiving anti-TNF alpha therapy for their rheumatologic diseases between April 2005 and September 2006. Of all the subjects, 45 had rheumatoid arthritis, 36 had ankylosing spondylitis, and 5 had psoriatic arthritis. In addition to anti-TNF alpha therapy, 60 of the 86 patients were given INH intervention for revealed latent tuberculosis. INH at a dosage of 300 mg daily was given for 9 months. Hepatotoxicity due to the INH therapy was considered when the serum alanine aminotransferase (ALT) and/or aspartate aminotransaminase (AST) levels showed at least threefold increase with respect to their baseline serum levels. Serum ALT and AST levels were measured by enzymatic colorimetric method in fasting peripheral blood samples at 0 (baseline), 1, 2, 3, 6, and 9 months. Of 86 patients, 47 (54.7%) were women (mean age +/- SD, 44.+/- 10.9 years) and 39 (45.3%) were men (38.8 +/- 10.1 years). Except five patients (8.3%), liver toxicity due to the INH therapy was not encountered among the patients, and after temporarily discontinuing the INH therapy of these five subjects, serum transaminase levels returned to the normal ranges. No hepatotoxicity was observed in the non-INH group. However, there was no statistical significance between INH-treated and non-INH-treated group (p=0.317). In addition, none of the 86 patients developed active tuberculosis infection during the treatment period. In conclusion, for those patients who were assigned to the TNF alpha treatment for their rheumatologic disorders and carrying risk for latent tuberculosis, INH intervention therapy was found to be safe and efficacious.
Published: 2007
Full Text: View/download PDF

26. Transudative chylothorax in a patient with pulmonary hypertension

Author: Efraim Güzel, Ismail Hanta, Oya Baydar, and Sedat Kuleci
Subjects: medicine.medical_specialty, Chyle, Pleural effusion, business.industry, Chylothorax, Triglyceride level, medicine.disease, Chest pain, Pulmonary hypertension, respiratory tract diseases, Surgery, Right hemithorax, Right heart failure, medicine, medicine.symptom, business
Abstract: Introduction: Chylothorax is defined by the presence of chyle in the pleural space. Transudative chylothorax has been reported between %15 - %32 of all chylothorax cases. In this report, we present a case of transudative chylothorax possibly developed from pulmonary hypertension due to cardiac valvular insufficiency and right heart failure. Case Presentation: A seventy years old, female patient admitted to our hospital with symptoms of dyspnea, right-sided chest pain for last 6 months. On chest radiography, pleural effusion covering nearly half of the right hemithorax was observed. Closed chest tube drainage was performed for relieving excessive pleural effusion. Since the color of pleural effusion appeared to be milky, pleural effusion was evaluated biochemically for chylothorax. Triglyceride level was found three fold higher than normal, but pleural effusion was transudative. Discussion: Chylothorax does not always meet the exudative criteria. Transudative form has been reported between %15-32 in several studies due to various pathologies. Since now, only two cases of transudative chylothorax due to pulmonary hypertension secondary to right heart failure have been reported. The possible mechanism for transudative chylothorax is poorly understood. Although very rare, evaluation of transudative pleural effusion for chylothorax should be considered in any patient with pulmonary hypertension with pleural effusion in clinical practice.
Published: 2015
Full Text: View/download PDF

27. Clinical characteristics and health burden of patients with chronic obstructive pulmonary disease exacerbation

Author: Ismail Hanta, Sedat Kuleci, Gulsah Seydaoglu, Oya Baydar, and Efraim Güzel
Subjects: medicine.medical_specialty, COPD, Exacerbation, business.industry, Anemia, High mortality, Pulmonary disease, Disease, medicine.disease, Pneumonia, Internal medicine, Intensive care, medicine, Intensive care medicine, business
Abstract: Introduction: Chronic obstructive pulmonary disease (COPD) exacerbation is an important factor in both mortality/morbidity and also health burden of the disease. In this study, we aimed to research the characteristics and heallth burden of the patients admitted to our hospital with COPD exacerbation within last 1 year. Methods: In our study, sociodemographic characteristics, clinic and laboratory findings of COPD exacerbation patients within the last one year are collected retrospectively. Health burden is calculated in terms of discharge bills in TL. Results: 40 patients enrolled in the study. 33 (82,5%) were males. 16 of them (40%) had co existing pneumonia. Only 4 (10%) and 5 (12,5%) of them were vaccinated against influenza and pneumococi respectively. In the last 1 year 29 (72,5%) of the participants had at least one exacerbation and 24 (60%) had hospitalized at least once. 22 (55%) had anemia. 9 of the cases has been cared in intensive care units and 4 (10%) cases had died. The mean cost of each patient was 1733,2 TL (min-max: 373,8-7348,7 TL). Conclusion: In conclusion; the unexpected high frequency of anemia, frequent coexistance with pneumonia and the high mortality of COPD exacerbations have been pointed out.
Published: 2015
Full Text: View/download PDF

28. Oxidant–Antioxidant Balance in Patients with COPD

Author: Ali Kocabas, Ismail Hanta, Gulsah Seydaoglu, Necmiye Canacankatan, Sedat Kuleci, and Çukurova Üniversitesi
Subjects: Male, Pulmonary and Respiratory Medicine, medicine.medical_specialty, Pathology, Erythrocytes, MDA, Comorbidity, medicine.disease_cause, Gastroenterology, Antioxidants, Superoxide dismutase, Pathogenesis, Lipid peroxidation, Pulmonary Disease, Chronic Obstructive, chemistry.chemical_compound, Malondialdehyde, Internal medicine, medicine, Humans, COPD, SOD, Aged, biology, Superoxide Dismutase, business.industry, Smoking, Venous blood, Middle Aged, medicine.disease, Enzyme assay, respiratory tract diseases, chemistry, Oxidative stress, biology.protein, Female, business
Abstract: PubMedID: 16622773 The goal of this study was to evaluate the role of oxidant-antioxidant balance in the pathogenesis of COPD. We included 30 healthy nonsmokers [24 male, 6 female; mean age (yr) ± SD: 62.4 ± 9.3], 30 healthy smokers [27 male, 3 female; mean age (yr) ± SD: 58.7 ± 6.0], 71 patients with stable COPD [68 male, 3 female; mean age (yr) ± SD: 63.5 ± 7.9], and 31 patients with COPD exacerbation [30 male, 1 female; mean age (yr) ± SD: 64.2 ± 7.3]. In all study groups the peripheral venous blood samples were taken for plasma malonyldialdehyde (MDA), a parameter of lipid peroxidation caused by the oxidants, and erythrocyte superoxide dismutase (SOD), an antioxidant enzyme. The mean plasma MDA level was higher in healthy smokers and in patients with COPD than in healthy nonsmokers (p < 0.05), and erythrocyte SOD enzyme activity in patients with COPD exacerbation (1048.2 ± 226.5 Ug/Hb) was significantly higher than in healthy nonsmokers (947.9 ± 198.0 Ug/Hb) (p < 0.05). Although mean erythrocyte SOD enzyme activity in healthy smokers and patients with stable COPD was higher than in healthy nonsmokers, the difference was not statistically significant. We found that healthy smokers and stable and exacerbated COPD patients had an impairment in oxidant-antioxidant balance. We suggested that new therapeutic interventions, which may repair the impaired oxidant-antioxidant balance in COPD, are needed to prevent the development of COPD. © Springer Science+Business Media, Inc. 2006.
Published: 2006
Full Text: View/download PDF

29. Basaloid large cell lung carcinoma presenting concurrently with metastatic uveal tumor

Author: Merih Soylu, Serap Hastürk, Ismail Hanta, E. Handan Zeren, and Çukurova Üniversitesi
Subjects: Male, Uveal Neoplasms, Pulmonary and Respiratory Medicine, Cancer Research, Pathology, medicine.medical_specialty, Lung Neoplasms, Paclitaxel, Pleural effusion, Carboplatin, Metastasis, Carcinoma, medicine, Humans, Radionuclide Imaging, Lung cancer, Tomography, Hilar Mass, Cancer, business.industry, Large cell, Smoking, Ocular symptoms, Combination chemotherapy, Middle Aged, medicine.disease, Magnetic Resonance Imaging, eye diseases, Pleural Effusion, Malignant, Oncology, Basaloid Large Cell Lung Carcinoma, Carcinoma, Large Cell, business
Abstract: PubMedID: 11282434 A 51-year-old man complaining of cough, hemoptysis, and decreased visual acuity was admitted to our hospital. Chest radiography revealed a left hilar mass and pleural effusion in the left hemithorax. In his ophtalmological examination, there was total retinal detachment in the left eye. Ultrasonographic examination and orbital magnetic resonance imaging (MRI) were reported as choroidal metastasis. A computed tomography (CT) confirmed the mass in the left hilum and multiple mass lesions consistent with metastasis in the liver and in the body of 12th thoracic vertebra. Bronchoscopic biopsies revealed large cell carcinoma with basaloid features. He died after 4 months with rapid progression of the disease in spite of combined chemotherapy. Although primary lung cancer with concurrent eye metastasis is an uncommon entity, it should always be kept in mind for patients with ocular symptoms. Copyright © 2001 Elsevier Science Ireland Ltd.
Published: 2001
Full Text: View/download PDF

30. OP-161 Ultrasound Accelerated Thrombolysis May be an Effective and Safe Treatment Modality for Intermediate Risk/Submassive Pulmonary Embolism

Author: Rabia Eker Akilli, Mesut Demir, Onur Sinan Deveci, Nezihat Rana Dişel, Caglar Ozmen, Ali Deniz, Caglar Emre Cagliyan, Ayca Acikalin Akpinar, Ismail Hanta, Huseyin Tugsan Balli, Mehmet Kanadaşı, Aziz Inan Celik, Ayhan Usal, and Halil Aktas
Subjects: medicine.medical_specialty, business.industry, medicine.medical_treatment, Ultrasound, Thrombolysis, medicine.disease, Pulmonary embolism, Surgery, Treatment modality, medicine, Radiology, Cardiology and Cardiovascular Medicine, business, Intermediate risk
Published: 2015
Full Text: View/download PDF

31. [Endobronchial capillary hemangioma: a very rare cause of massive hemoptysis]

Author: Ismail Hanta, Ezgi Ozyilmaz, Dilek Yunsel, Sedat Kuleci, and Ali Kocabas
Subjects: Pulmonary and Respiratory Medicine, Male, medicine.medical_specialty, Hemoptysis, Critical Care and Intensive Care Medicine, Benign tumor, Diagnosis, Differential, Bronchoscopy, Biopsy, medicine, Bronchial neoplasm, Humans, In patient, Hemangioma, Capillary, medicine.diagnostic_test, business.industry, Capillary hemangioma, Bronchial Neoplasms, respiratory system, Middle Aged, medicine.disease, eye diseases, Male patient, Surgery, sense organs, Radiology, Differential diagnosis, business
Abstract: Tracheal capillary hemangioma is a very rare benign tumor of trachea which may present as massive hemoptysis. Minor to massive hemoptysis can be observed in these patients. Due to its small size and tracheal localization, diagnosis cannot be easily performed by using radiological investigations. Fifty-years-old male patient who was diagnosed as tracheal capillary hemangioma with bronchoscopic biopsy was presented in this case report. According to our knowledge, this is the eighth case report in the world literature. Tracheal capillary hemangioma must be kept in mind in patients with massive hemoptysis with normal radiologic features and bronchoscopic procedures (excision, argon, laser etc.) should be the first choice of therapy when diagnosed.
Published: 2012

32. The Effect Of Obesity On Pulmonary Functions In Patients With Severe COPD

Author: Sedat Kuleci, Ismail Hanta, Müjde Cigerci, Ezgi Ozyilmaz, and Ali Kocabas
Subjects: medicine.medical_specialty, business.industry, Internal medicine, medicine, In patient, Severe copd, business, medicine.disease, Obesity
Published: 2012
Full Text: View/download PDF

33. The Effect Of Obesity On Asthma Control And Pulmonary Functions In Patients With Asthma

Author: Ali Kocabas, Ezgi Ozyilmaz, Ismail Hanta, Oya Baydar, and Sedat Kuleci
Subjects: medicine.medical_specialty, business.industry, Internal medicine, Asthma control, medicine, In patient, medicine.disease, business, Obesity, Asthma
Published: 2012
Full Text: View/download PDF

34. Detection of latent tuberculosis infection in rheumatologic diseases before anti-TNF? therapy: Tuberculin skin test versus IFN-? assay

Author: Sedat Kuleci, Ezgi Ozyilmaz, Ismail Hanta, Gulsah Seydaoglu, Süleyman Özbek, and Çukurova Üniversitesi
Subjects: Adult, Male, medicine.medical_specialty, Immunology, Tuberculin, Interferon-gamma assays, Gastroenterology, QuantiFERON, Interferon-gamma, Rheumatology, Rheumatic Diseases, Internal medicine, medicine, Humans, Immunology and Allergy, In patient, Latent tuberculosis, Tuberculin skin test, Tuberculin Test, business.industry, Skin test, Middle Aged, medicine.disease, bacterial infections and mycoses, Peripheral blood, Rheumatologic diseases, Female, Tumor necrosis factor alpha, business
Abstract: PubMedID: 22095393 We aimed to evaluate tuberculin skin test (TST) and interferon-gamma (IFN-?) test results for latent tuberculosis infection (LTBI) in patients with rheumatologic diseases prior to anti-TNF? therapy. Ninety patients were evaluated in the study at the Departments of Chest Diseases and Rheumatology for anti-TNF? therapy for their rheumatologic diseases. Tuberculin skin test was performed (Mantoux method) and peripheral blood samples were collected for IFN-? assay (QuantiFeron TB-Gold In Tube) before the anti-TNF? therapy. Of 90 patients, TST positivity was detected in 56 (62.2%) patients, while IFN-? positivity was detected in 34 (37.8%) patients. Among 56 TST positive patients, IFN-? positivity was detected in 24 (42.9%) patients, and among 34 TST negative patients, IFN-? positivity was detected in 10 (29.4%) patients. There was no significant agreement between TST and IFN-? assay results (Kappa = 0.12, P = 0.2). Forty-three (47.8%) patients were using immunosuppressive drugs owing to their rheumatologic diseases. In this group, TST and IFN-? positivity is significantly lower than in those who did not receive immunosuppressive treatment (P
Published: 2012

35. Tuberculin Skin Test Positivity Among Patients With Rheumatologic Diseases: Experienced With 609 Patients

Author: Sedat Kuleci, Ismail Hanta, and Süleyman Özbek
Subjects: medicine.medical_specialty, business.industry, medicine, Tuberculin, Skin test, business, Dermatology, Surgery
Published: 2010
Full Text: View/download PDF

36. The Prevalence Of Metabolic Syndrome In Patients With COPD

Author: Sedat Kuleci, Yasemin Soydas, Ali Kocabas, Ismail Hanta, and Gulsah Seydaoglu
Subjects: COPD, medicine.medical_specialty, business.industry, Internal medicine, medicine, In patient, Metabolic syndrome, medicine.disease, business
Published: 2010
Full Text: View/download PDF

37. The Course of the Prevalence of Asthma Symptoms in Adolescents by Gender

Author: Ali Kocabas, Ismail Hanta, Gulsah Seydaoglu, T. Gocmen, Sedat Kuleci, and Çukurova Üniversitesi
Subjects: Pediatrics, medicine.medical_specialty, business.industry, Medicine, Asthma symptoms, business
Abstract: WOS: 000208733104273 …
Published: 2009

38. The effect of different treatment modalities on oxidative stress in COPD

Author: Ismail Hanta, Ali Kocabas, Necmiye Canacankatan, Sedat Kuleci, and Çukurova Üniversitesi
Subjects: Male, medicine.medical_specialty, Adrenergic beta-Antagonists, Superoxide dismutase, Ipratropium bromide, medicine.disease_cause, Placebo, Gastroenterology, Methylprednisolone, chemistry.chemical_compound, Basal (phylogenetics), Pulmonary Disease, Chronic Obstructive, Internal medicine, Malondialdehyde, medicine, Humans, COPD, Corticosteroids, Pharmacology (medical), Glucocorticoids, Aged, biology, business.industry, Ipratropium, General Medicine, Free Radical Scavengers, Middle Aged, medicine.disease, N-acetylcysteine, Acetylcysteine, Respiratory Function Tests, chemistry, Oxidative stress, Anesthesia, biology.protein, Drug Therapy, Combination, Female, business, medicine.drug
Abstract: PubMedID: 18592146 Introduction: Oxidant/antioxidant interactions are known to be important processes in the pathogenesis of chronic obstructive pulmonary disease (COPD). We aimed to evaluate the effects of corticosteroids (CS), and N-acetylcysteine (NAC) on plasma oxidant/antioxidant levels in patients with COPD. Methods: This study utilised a single-blind, randomised, placebo-controlled, parallel-group methodology. We enrolled 58 patients with stable COPD and 30 healthy controls with similar demographic profiles. The patients with COPD were randomly divided into three treatment groups. Group 1 received basal treatment (regular ipratropium bromide and beta-2 agonist as needed), placebo CS and placebo NAC. In addition to basal treatment, group 2 received oral CS (methylprednisolone 40 mg/day) and placebo NAC. Group 3 received basal treatment plus NAC (600 mg/day) and placebo CS. Each group received treatment for 15 days. We measured plasma malondialdehyde (MDA) and superoxide dismutase (SOD) at the start and the end of study. Results: Post-treatment plasma MDA levels were significantly lowered only in group 2 (P=0.004). No significant differences were found with respect to erythrocyte SOD levels. Conclusion: This study demonstrates that oral CS, by aiding the oxidant/antioxidant system, may offer a new therapeutic option in COPD treatment. The page charges for this article were funded by Sanofi Pasteur Turkey, Acetelion Turkey, Novartis Turkey, and the authors.
Published: 2008

39. The evaluation of latent tuberculosis in rheumatologic diseases for anti-TNF therapy: Experience with 192 patients

Author: Ismail Hanta, Süleyman Özbek, Ali Kocabas, Sedat Kuleci, and Çukurova Üniversitesi
Subjects: Adult, Male, medicine.medical_specialty, Tuberculin, Physical examination, Antibodies, Arthritis, Rheumatoid, Psoriatic arthritis, Rheumatology, Internal medicine, Medicine, Humans, Tuberculosis, Spondylitis, Ankylosing, Latent tuberculosis infection, Ankylosing spondylitis, Latent tuberculosis, medicine.diagnostic_test, Tuberculin skin test, business.industry, Tuberculin Test, Tumor Necrosis Factor-alpha, Isoniazid, Arthritis, Psoriatic, Anti-TNF therapy, General Medicine, medicine.disease, bacterial infections and mycoses, Surgery, Rheumatoid arthritis, Female, Radiography, Thoracic, business, medicine.drug
Abstract: PubMedID: 18320137 It is recommended to evaluate the presence of latent tuberculosis infection (LTBI) before initiating antitumor necrosis factor ? (anti-TNF) therapy for rheumatologic diseases. We aimed to present the follow-up results of 192 patients with rheumatologic diseases before anti-TNF therapy for LTBI. We enrolled 192 patients who were given anti-TNF therapy for their rheumatologic diseases between April 2005 and January 2008. The demographic characteristics of the patients were recorded. Chest X-ray was obtained and tuberculin skin test (TST) was performed in all patients before anti-TNF therapy. LTBI was assessed by detailed history of close contact with infectious cases within the last year, abnormal chest radiography, and positive TST (?5 mm) before initiating anti-TNF therapy. Patients with anti-TNF therapy were followed with 2-month intervals for active tuberculosis by pulmonary and extrapulmonary symptoms, physical examination, and chest X-ray. Of 192 patients, 104 (54.2%) patients were women, age (mean±SD) 43.1±12.7 years and 88 (45.8%) patients were men, age (mean±SD) 39.3±11.2 years. Ninety-one (47.4%) of them had rheumatoid arthritis (RA); 92 (47.9%) had ankylosing spondylitis (AS), and nine (4.7%) had psoriatic arthritis. Isoniazid treatment was started in 129 (67.2%) patients in whom LTBI was detected. No significant difference was observed for TST positivity (TST±5 mm) between the patients with RA and AS (p = 0.101). Similarly, no significant difference was also observed for TST positivity between the patients who received immunosuppressive therapy and those who did not (p = 10.154). Only three (1.6%) patients developed active tuberculosis at the study period. We suggested that in despite of the presence of rheumatologic disease and/or immunosuppressive therapy, TST is an acceptable and available diagnostic test for detecting LTBI before anti-TNF therapy. © Clinical Rheumatology 2008.
Published: 2008

40. Abdominal compartment syndrome: current problems and new strategies

Author: Ismail Hanta, Emre Karakoc, Ali Haydar Alparslan, Cem Kaan Parsak, Gulsah Seydaoglu, Gurhan Sakman, Salim Satar, T. Oguz Acarturk, and Çukurova Üniversitesi
Subjects: musculoskeletal diseases, Adult, Male, medicine.medical_specialty, Abdominal compartment syndrome, Turkey, Comorbidity, Compartment Syndromes, Sensitivity and Specificity, Statistics, Nonparametric, Abdomen, Medicine, Humans, Prospective Studies, Prospective cohort study, APACHE, Aged, Monitoring, Physiologic, Proportional Hazards Models, Aged, 80 and over, APACHE II, business.industry, Middle Aged, medicine.disease, Decompression, Surgical, Confidence interval, Surgery, Cardiac surgery, body regions, Survival Rate, Treatment Outcome, ROC Curve, Cardiothoracic surgery, Anesthesia, Arterial blood, Female, business, Abdominal surgery
Abstract: PubMedID: 18026790 Background: Abdominal compartment syndrome (ACS) is a diffucult entity with two main problems during its course: (1) survival of the patient during the early period and (2) closure of the open wounds during the late period. In this study we evaluated the decision to decompress according to the level of intraabdominal pressure (IAP) and analysis of any recurrent or persistent increase in IAP. Methods: A prospective study was undertaken on 119 patients with increased IAP. The IAP was measured daily by obtaining the bladder pressure. Patients were monitored via a central venous line; and vital signs, arterial blood gases, the Acute Physiology, Age, and Chronic Health Evaluation II (APACHE II) score, and abbreviated mental tests were recorded. The suggestions of Meldrum et al. were taken as a guideline during the treatment. The sensitivity and specifity of IAP and APACHE II scores for different cutoff values were calculated using the receiver operating characteristic curve. Results: Hospital mortality was 33.6%, which increased with co-morbidities (p = 0.03). A cutoff value for IAP of 23 mmHg was considered an optimal point predicting mortality. The IAP within the first 3 days for patients who died was higher than the cutoff value. For patients with IAP of 15 to 25 mmHg, nonsurgical therapy increased the rate of mortality (odds ratio 5.2, 95% confidence interval 1.0-27.7; p = 0.03). Conclusions: In patients with ACS emergency, it is recommended that decompressive laparotomy to be performed even if the IAP falls below 25 mmHg. For patients with IAP levels higher than 25 mmHg, the IAP should be meticolusly brought below the cutoff level during the postoperative period. © 2007 Société Internationale de Chirurgie.
Published: 2007

41. Effectiveness of nitric oxide derivates in hydatid disease

Author: Tolga Akcam, Gurhan Sakman, Ömer Alabaz, Sedat Kuleci, Ismael Soner Koltas, Ismail Hanta, Cem Kaan Parsak, and Çukurova Üniversitesi
Subjects: inorganic chemicals, Pathology, medicine.medical_specialty, Immune status, biology, business.industry, Gastroenterology, Disease, nitric oxide derivates, biology.organism_classification, Nitric oxide, immunology, chemistry.chemical_compound, Echinococcus, chemistry, hydatid disease, nitrate, parasitic diseases, medicine, Surgery, business, nitrite
Abstract: Background: The purpose of this study was to assess the possible alterations of the levels of plasma NO derivates which are thought to reflect the immune status of the body against cystic echinococcus (CE). Materials and Methods: Plasma NO2 and NO3 levels of 95 patients with CE were analyzed before treatment and then after a 1 year. All patients were classified according to the WHOIWGE classification of cystic hydatid disease. The levels of NO2 and NO3 were detected from sera by using a photometric endpoint determination on the basis of absorbance in the visible range at 550 nm. Results: Pretreatment levels of plasma NO2 and NO3 of the CE group were significantly higher than those in the control group (p < 0.001). However, the posttreatment NO2 and NO3 levels of the CE group were significantly lower than the pretreatment levels (p < 0.001). Hence, a positive correlation was found between fertile capacity of CE and the levels of NO2 and NO 3 (p < 0.05). Conclusion: The analysis of the levels of plasma NO derivates should be considered for the at preoperative detection of hydatid disease and postoperative follow-up in addition to radiological and serological methods. © 2007 S. Karger GmbH.
Published: 2007

42. Huge bilateral pulmonary and pleural metastasis from intracranial meningioma: a case report and review of the literature

Author: Sebahattin Hacıyakupoğlu, Ismail Hanta, Suzan Zorludemir, Handan Zeren, Tahsin Erman, A. İskender Göçer, and Çukurova Üniversitesi
Subjects: Adult, Cancer Research, medicine.medical_specialty, Pathology, Lung Neoplasms, Malignant meningioma, medicine.medical_treatment, Pleural Neoplasms, Metastasis, Meningioma, Biopsy, medicine, otorhinolaryngologic diseases, Meningeal Neoplasms, Humans, neoplasms, Lung, medicine.diagnostic_test, business.industry, medicine.disease, Magnetic Resonance Imaging, nervous system diseases, Radiation therapy, medicine.anatomical_structure, Neurology, Oncology, Cytopathology, Pleura, Female, Neurology (clinical), Radiology, business, Tomography, X-Ray Computed, Recurrent Meningioma
Abstract: PubMedID: 16193389 A case of recurrent meningioma with atypical features and extracranial metastases is reported. A 34-year-old female was operated in 1996, 2000, and 2002, and frontal parasagital meningioma was extirpated. Histological diagnoses of all the resected tumors were meningotheliomatous meningioma, WHO Grade I. However, 2 years later, the tumor recurred in the frontal scalp and was removed again totally. Histological diagnosis was reported as an atypical meningioma; meningotheliomatous type; WHO Grade II. She received radiation therapy. But the tumor had metastasized to the lung and pleura. Transthoracic tru-cut biopsy was performed from large mass of the left lung. Cytopathology was consistent with malignant meningioma, metastasis from the patient's known intracranial meningioma. Ki-67 staining index at the primary and metastatic sites of the present cases were 7 and 5%, respectively. We reviewed and discussed the histopathological features and mechanisms of metastasizing meningioma. © Springer 2005.
Published: 2005

43. Is sildenafil effective in secondary pulmonary hypertension due to systemic lupus erythematosus? A case report

Author: Mesut Demir, Süleyman Özbek, Ismail Hanta, Ali Kocabas, Onur Akpinar, and Çukurova Üniversitesi
Subjects: chemistry.chemical_compound, medicine.medical_specialty, Rheumatology, chemistry, Sildenafil, business.industry, Internal medicine, Medicine, General Medicine, Secondary pulmonary hypertension, business
Abstract: PubMedID: 15951919 [No abstract available]
Published: 2005

44. Superior vena cava syndrome: a rare clinical manifestation of Behcet's disease

Author: Gamze Ucar, Süleyman Özbek, Ali Kocabas, Ismail Hanta, Sedat Kuleci, and Çukurova Üniversitesi
Subjects: Adult, Male, medicine.medical_specialty, Superior Vena Cava Syndrome, Prednisolone, Superior vena, Clinical manifestation, Behcet's disease, Diagnosis, Differential, Rheumatology, Internal medicine, Popliteal vein, medicine, Humans, Ultrasonography, Doppler, Color, Cyclophosphamide, Glucocorticoids, Retrospective Studies, Superior vena cava syndrome, business.industry, Behcet Syndrome, General Medicine, medicine.disease, Magnetic Resonance Imaging, Drug Therapy, Combination, Radiology, medicine.symptom, business, Tomography, X-Ray Computed, Immunosuppressive Agents, Follow-Up Studies
Abstract: PubMedID: 15349796 [No abstract available]
Published: 2003

45. The Oxidant-Antioxidant Balance in Mild Asthmatic Patients

Author: Ismail Hanta, Sedat Kuleci, Ali Kocabas, Necmiye Canacankatan, and Çukurova Üniversitesi
Subjects: Pulmonary and Respiratory Medicine, Adult, Male, medicine.medical_specialty, Antioxidant, Erythrocytes, Turkey, medicine.medical_treatment, medicine.disease_cause, Severity of Illness Index, Antioxidants, Superoxide dismutase, Lipid peroxidation, chemistry.chemical_compound, Adrenal Cortex Hormones, Predictive Value of Tests, Internal medicine, Forced Expiratory Volume, Malondialdehyde, Administration, Inhalation, Medicine, Humans, Balance (ability), Asthma, Skin Tests, biology, business.industry, Superoxide Dismutase, Venous blood, MDA and SOD, medicine.disease, Oxidants, Enzyme assay, Respiratory Function Tests, Endocrinology, Treatment Outcome, chemistry, Oxidative stress, Immunology, biology.protein, Female, Lipid Peroxidation, business, Biomarkers
Abstract: PubMedID: 14749939 We investigated the oxidant-antioxidant balance and the effect of inhaled corticosteroids on this balance in mild stable asthmatics. Included in the study were 30 mild asthmatic patients (11 male, 19 female, mean age (year) ± SD: 35.1 ± 9.7) and 26 healthy adults (7 male, 19 female, mean age (year) ± SD: 40.8 ± 13.3). In all study groups, the peripheral venous blood samples were taken for plasma malonyldialdehyde (MDA), a parameter of lipid peroxidation caused by the oxidants, and erythrocyte superoxide dismutase (SOD), an antioxidant enzyme. The mean plasma MDA level was lower in the asthmatic group (5.7 ± 1.2 nmol/ml) than in the healthy group (6.3 ± 1.7 nmol/ml); and the mean erythrocyte SOD level was higher in asthmatic group (1086.4 ± 247.4 U/gHb) than in the healthy group (1028.0 ± 230.0 U/gHb). However, there were no significant differences in measurements of both plasma MDA levels and erythrocyte SOD enzyme activities between the groups (respectively, p = 0.1 and p = 0.4). When asthmatic patients were divided into subgroups as "inhaled steroid user" and "no inhaled steroid user", no significant differences were observed in the measurements of either plasma MDA level or erythrocyte SOD enzyme activity between the mentioned subgroups. According to the results of our study, we can say that oxidant-antioxidant balance is not significantly affected in mild asthmatics or measurement of plasma level of MDA and erythrocyte SOD enzyme activity is not sensitive to the oxidant-antioxidant balance in mild asthmatics.
Published: 2003

46. Granulomatous reaction after chemotherapy for Hodgkin's disease

Author: Umut Disel, Serap Hastürk, Ismail Hanta, Semra Paydas, Berksoy Sahin, Handan Zeren, Sinan Yavuz, Melek Ergin, and Çukurova Üniversitesi
Subjects: Male, Cancer Research, Systemic disease, Pathology, medicine.medical_specialty, Sarcoidosis, Pleural effusion, Constitutional symptoms, medicine.medical_treatment, Antineoplastic Agents, Blood Sedimentation, Diagnosis, Differential, Sarcoidosis, Pulmonary, Macroglobulins, hemic and lymphatic diseases, Humans, Medicine, Chemotherapy, business.industry, Hematology, Middle Aged, medicine.disease, Hodgkin Disease, Lymphoma, Radiography, Oncology, ABVD, Lymph, Radiology, business, medicine.drug
Abstract: There are some reports that relate the coexistence of sar-coidosis and lymphoma. This coexistence has been calledthe sarcoidosis–lymphoma syndrome. Generally, sarcoido-sis precedes the lymphoma in these cases. On the other handthere are some other reports about sarcoidosis or sarcoid likereaction following the therapy of lymphoma. We report herea case with sarcoid like reaction developing after systemicchemotherapy for Hodgkin’s disease (HD) and discuss thepossible deﬁnitions.1. Case reportA 55-year-old man was admitted to our hospital withrelapsed HD. He had a history of lymphocyte rich-HD dia-gnosed in November 1999. He had cervical and abdomi-nal lymph nodes, right pleural effusion, splenomegaly andconstitutional symptoms. He had the history of six coursesof ABVD chemotherapy at another hospital. Cervical, tho-racic and abdominal CT scans were found to be normaland 2-microglobulin ( 2M) was within normal limits(2772ng/ml) after chemotherapy. Two months later he com-plained of constitutional symptoms and at that time, CTscans showed cervical, intraabdominal and retroperitoneallymph nodes, splenomegaly and mediastinal lymph nodes.Physical examination disclosed cervical and inguinallymph nodes. Laboratory results: Hb was 11.7g/dl, Hctwas 35.4%, WBC was 10 × 10
Published: 2002

47. P-094 Gemcitabine, vinorelbine and cisplatin combination chemotherapy in advanced non-small cell lung cancer

Author: Ismail Hanta, Serap Hastürk, Nilgun Hatabay, Ferah Ece, and M. Karatas
Subjects: Pulmonary and Respiratory Medicine, Oncology, Cisplatin, Cancer Research, medicine.medical_specialty, business.industry, Combination chemotherapy, medicine.disease, Gemcitabine/Vinorelbine, Internal medicine, Medicine, Non small cell, business, Lung cancer, medicine.drug
Published: 2005
Full Text: View/download PDF

48. Late Bilateral Endobronchial Metastasis Due to Rectum Cancer

Author: Ismail Hanta
Subjects: Pulmonary and Respiratory Medicine, medicine.medical_specialty, business.industry, General surgery, Rectum, Cancer, Critical Care and Intensive Care Medicine, medicine.disease, medicine.anatomical_structure, Endobronchial metastasis, Rectal carcinoma, Medicine, Radiology, Cardiology and Cardiovascular Medicine, business
Published: 2013
Full Text: View/download PDF

49. Huge Bilaterally Cavitary and Nodulary Lung Lesions: Pulmonary Lymphomatoid Granulomatosis

Author: Müesser Parsak and Ismail Hanta
Subjects: Pulmonary and Respiratory Medicine, Pathology, medicine.medical_specialty, Lymphomatoid granulomatosis, Lung, medicine.anatomical_structure, business.industry, Medicine, Pulmonary Lymphomatoid Granulomatosis, Cardiology and Cardiovascular Medicine, Critical Care and Intensive Care Medicine, business, medicine.disease
Published: 2013
Full Text: View/download PDF

50. P2-075: Prognostic significance of COX-2 and VEGF expression in lung cancer

Author: Serap Hastürk, Elif Guveloglu, Ismail Hanta, Gamze Ucar, Handan Zeren, and Sedat Kuleci
Subjects: Pulmonary and Respiratory Medicine, Oncology, business.industry, Cancer research, medicine, Vegf expression, Lung cancer, medicine.disease, business
Published: 2007
Full Text: View/download PDF

Catalog

Books, media, physical & digital resources

See catalog results

Searchworks

Select search scope, currently: Articles Catalog books, media & more in Jio Institute collections Articles journal articles & other e-resources

Search

Search Constraints

Refine your results

Search Limiters

Topic

Publication Year Range

Language

Journal

Database

Publisher

51 results on '"Ismail Hanta"'

Search Results

Catalog

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources